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EXECUTIVE SUMMARY 
1. SPECIFIC AIMS 
 Psychiatric polypharmacy refers to the prescription of two or more psychiatric 
medications concurrently to a patient for the treatment of a single condition (Shrivastava, 
Kukreja, Kalra, & Shah, 2013). The major concerns associated with the use of polypharmacy 
include: risk of medication-related adverse events, complicated drug regimen affecting patient 
compliance, drug-drug interactions, cumulative toxicity, and patient morbidity and mortality 
(Maher, Hanlon, & Hajjar, 2013). According to the American Academy of Child and Adolescent 
Psychiatry “little data exists to support advantageous efficacy for drug combinations,” and, 
“current clinical ‘state-of-the-art’ supports judicious use of combined medications, keeping such 
use to clearly justifiable clinical circumstances” (AACAP, 2001; Zonfrillo, Penn, & Leonard, 
2005). Clinical guidelines recommend monotherapy as the preferred therapy in psychiatric 
practice. Despite these recommendations the use of psychiatric polypharmacy is quite common 
in clinical practice with the overall prevalence ranging from 13%-90% (Chen, Patel, Sherer, & 
Aparasu, 2011).  
 Due to the growing concerns of polypharmacy and off-label use of psychotropic 
medications in children and adolescents, 42 states of the United States have developed programs 
to manage/monitor the appropriate use of psychotropic medications (CMS, 2014). The Texas 
child welfare system released a “best practices” guide to ensure appropriate use of psychotropic 
medications for children in foster care in February 2005 which was updated in 2007, 2010 and 
2013 (DFPS, 2016). In 2014, the Texas Health and Human Services Commission modified 
Section 8.1.21.6 of its Uniform Managed Care Terms and Conditions and made the Psychotropic 
Medication Utilization Review (PMUR) a mandatory process for Medicaid Managed Care 
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Organizations (MCOs). The PMUR involves monitoring of “guideline non-concordant” 
prescribing of psychotropic medications in children, specifically focusing on the use of 
psychotropic polypharmacy (Psychotropic Medication Utilization Parameters, 2016).  
The existing PMUR process views guideline non-concordant prescribing as the outcome 
of individual providers’ knowledge and attitude. Once a provider with frequent guideline non-
concordant prescribing is identified, he/she is referred to further investigation conducted by 
medical professionals from the health plan and if warranted disciplinary action including 
termination from the network may be implemented (DFPS, 2016). However, these investigations 
do not consider the effect of the environment from which such behavior originated. Additionally, 
though these review procedures are effective in changing physicians’ prescribing behavior, they 
are resource intensive. The review committees of most MCOs only have the capacity to review 
and reach out to a small fraction among thousands of contracted providers. Further, the 
individual focused PMUR fails to acknowledge that some guideline non-concordant uses, 
especially polypharmacy could arise from poor communication among providers rather than due 
to the individual’s prescribing behavior.  
Physicians are not isolated individuals but part of a social structure who may be 
influenced.  Past studies have shown that the physicians’ prescribing behavior can be influenced 
by peers in addition to their own personal preferences. If there is a strong peer effect in the 
prescribing of psychotropic medications to children, targeting and changing the prescribing 
behavior of guideline non-concordant prescribers could lead to a cascading effect in guideline 
diffusion among other physicians within the network, resulting in increased concordance with 
guidelines. Social Network Analysis (SNA) is a set of theories and techniques used to understand 
how social relationships (e.g., friendship, advice seeking, and reputation) influence behaviors 
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(Gesell, Barkin, & Valente, 2013; Valente, 2010; Valente, Gallaher, & Mouttapa, 2004). SNA 
examines physicians’ behaviors in the context of their professional social structure (network) 
where they communicate, collaborate, compete and exert influences on each other. SNA 
provides a unique perspective to understand the underlying reasons of prescribing decisions and 
medication errors. It has the potential to address limitations of the existing PMUR program and 
to improve the quality of treatment for Medicaid enrolled children with mental disorders. 
Therefore, the objective of the proposed research is to examine the role of inter-provider 
relationships (communication, collaboration and peer influence) in guideline-non-concordant use 
of psychotropic medications. The specific aims of the research are:       
Aim I: To advance the understanding of the prevalence of and risk factors associated with long-
term multiclass psychotropic polypharmacy among children and adolescents with 
mental/behavioral disorders in a Texas Medicaid population. 
Aim II: Among children with mental/behavioral disorders who were prescribed psychotropic 
medications by multiple prescribers, to examine the relationship between care-density (patients’ 
care team cohesiveness) and receipt of psychotropic polypharmacy 
Hypothesis I: Patients with higher care-density (stronger care team cohesiveness) will 
have less likelihood of receiving multiclass psychotropic polypharmacy. 
Aim III: Among children with MHD who were prescribed psychotropic medications by single 
prescriber, to examine the effect of physician peer-influence on the prescribing of psychotropic 
polypharmacy. 
Hypothesis II: The likelihood of prescribing psychotropic polypharmacy is affected by 
physician peer-influence based on both direct communication (affiliation exposure) and 
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comparison between peers who occupy similar network positions (structural equivalence 
exposure). 
2. BACKGROUND AND SIGNIFICANCE 
2.1 Background 
Definition of psychotropic polypharmacy: 
Polypharmacy is defined as the practice of prescribing or administering multiple 
medications concurrently in a single patient for the treatment of a single condition. The 
definition is solely based on the number of medications prescribed and does not take into account 
the clinical relevance or the adequacy of the proposed therapeutic regimen. The term 
polypharmacy suggests the use of more medications than is ‘clinically indicated’ (Shrivastava, 
Kukreja, Kalra, & Shah, 2013). Psychiatric polypharmacy is the practice of polypharmacy in 
psychiatric therapy. The most commonly used definition of psychiatric polypharmacy is the use 
of two or more psychiatric medications in the same patient, or the use of two or more psychiatric 
medications (of same chemical class or same pharmacological action) to treat the same condition 
(Shrivastava, Kukreja, Kalra, & Shah, 2013; NASMHPD, 2001).  
Short-term psychotropic polypharmacy: 
Despite the scarcity of evidence for or against the use of polypharmacy, there are 
instances where short-term polypharmacy is clearly appropriate or even necessary. The primary 
reason for prescribing more than one psychotropic agent for an extended period of time is when a 
single medication is not effective. However, before initiating on multiple psychotropic agents the 
patient should first receive adequate trials on a number of single medications as the clinical 
effect of the medication may not be seen until weeks. Usually, most medications require at least 
5 half-lives to reach a consistent concentration in the body. A valid trial period to determine the 
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effectiveness of a psychiatric medication is at least 21 days of continuous use on the same dose. 
Other situation when multiple psychotropic agents may be appropriate for short-term use is while 
changing a patient from one psychotropic agent to another. Usually clinicians intentionally either 
overlap or cross-titrate the two medications which results in a brief period of combination 
treatment. The old medication is concurrently used with the new until the new medication shows 
the desired effect. It is extremely important to avoid the ‘crossover trap’ in such situations where 
the patient shows clinical response before completion of the crossover and both medications are 
continued indefinitely (Disability Rights California, 2004; NASMHPD, 2001). 
General concerns of long-term psychotropic polypharmacy: 
Preskorn and Lacey (2007) listed a few conditions under which polypharmacy is 
justified: i) to treat two pathophysiologically distinct but comorbid disorders, ii) to treat an 
adverse effect produced by the primary drug, iii) to provide acute amelioration while awaiting 
the effect of another medication, iv) to treat intervening phases of an illness and v) as an adjunct 
to boost the efficacy of primary treatment and treat exacerbations of the illness (Preskorn & 
Lacey, 2007). In each of these circumstances, the combinations are used only to achieve the 
short-term goals as long-term use of polypharmacy often results in increased risk of adverse drug 
events (ADEs), drug-interactions, medication non-adherence, patient morbidity and mortality, 
and is highly likely to increase overall drug expenditures (Fontanella, Warner, Phillips, Bridge, 
& Campo, 2014; Khan & Preskorn, 2005; Maher, Hanlon, & Hajjar, 2013). Evidence based 
research and expert opinion caution clinicians about the risk associated with the use of 
polypharmacy. 
Adverse drug events: Taking several drugs contributes to the risk of having an ADE. In a 
population based study, patients taking ≥ 5 medications had an 88% increased risk of 
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experiencing an ADE compared to those who were taking fewer medications (Bourgeois, 
Shannon, Valim, & Mandl, 2010). In another study of nursing home residents, the rates of ADEs 
were twice as high as in patients taking ≥ 9 medications compared to those taking less number of 
medications (Nguyen, Fouts, Kotabe, & Lo, 2006). A study among veterans found that patients 
taking ≥ 5 medications were 4 times more likely to be hospitalized from an ADE (Marcum et al., 
2011). Another study in outpatient practices among elderly patients found that taking six or more 
medications increased the risk of adverse drug events by fourfold (Pretorius, Gataric, Swedlund, 
& Miller, 2013). The concurrent use of medications can amplify individual drug’s side effects. 
When used in combination two medications with mild sedative effects can cause significant 
sedation (Kramer, 2000). Similarly, concurrent use of drugs that cause mild weight gain may 
cause severe weight gain (Hashimoto et al., 2012; Kramer, 2000). Compared to monotherapy, 
antipsychotic polypharmacy is found to be associated with an increased risk of having pre-
metabolic syndrome, even after adjusting for patients’ lifestyle characteristics (Misawa et al., 
2011). It has been demonstrated that young age and polypharmacy have positive associations 
with an increased risk of obesity and cardiovascular, cerebrovascular or hypertensive adverse 
events (De Hert, Detraux, Winkel, Yu, & Correll, 2011). 
Drug-drug interactions: Combination of drugs may lead to pharmacokinetic and 
pharmacodynamic interactions in the body as presence of one drug might alter the nature, 
magnitude and the duration of effect of the other drug (Werder & Preskorn, 2003). The 
absorption, distribution, metabolism and excretion of one drug might be altered by the other drug 
thereby changing the blood levels of the other drug. In a prospective cohort study of hospitalized 
adults taking 5 or more medications, the prevalence of drug-drug interaction was 80%. The 
probability of the drug interactions increased with the number of medications, patients taking 5-
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20 medications had a 50%-100% probability of interaction (Doan, Zakrzewski-Jakubiak, Roy, 
Turgeon, & Tannenbaum, 2013; Maher, Hanlon, & Hajjar, 2013). Use of certain antipsychotics 
in combination with anticholinergic drugs may increase the anticholinergic effects of both drugs 
leading to confusion, dehydration, constipation, or development of fatal cholinergic crisis 
(Disability Rights California, 2004). A brief list of possible drug-drug interactions associated 
with psychotropic medications is listed in Table 1 (Sengul et al., 2014).  
Table 1: Interaction risk among drugs and associated outcome  
Outcome of 
interaction risk 
Interacting drugs 
QT prolongation a) citalopram with quetiapine /fluphenazine/ paliperidone /risperidone 
/pimozide /haloperidol 
b) ziprasidone with risperidone /quetiapine/ pimozide/ chlorpromazine 
c) quetiapine with lithium/ fluphenazine/ haloperidol/ pimozide 
d) clozapine with risperidone/ quetiapine/ haloperidol /aripiprazole 
/fluphenazine 
e) haloperidol with lithium/ chlorpromazine/ fluphenazine 
Change in Drug 
levels 
a) quetiapine-CBZ  interaction  
b) VAL–risperidone, VAL-TCA interaction  
c) CBZ with risperidone/aripiprazole/fluoxetine/  
d) sertraline/paroxetine/fluoxetine/citalopram/escitalopram with 
risperidone/aripiprazole/clozapine interaction  
e) lamotrigine and clozapine/ olanzapine/ risperidone interaction  
Hepatotoxicity Olanzapine and VAL interaction 
Bradycardia-
hypertension 
a) All interactions between benzodiazepines and olanzapine or clozapine  
b) All propranolol and biperidene/ quetiapine/ lithium or olanzapine 
interaction  
 
Non-adherence: Non-adherence with drugs in adults has been associated with the complicated 
drug regimens and polypharmacy (Hajjar, Cafiero, & Hanlon, 2007; Vik, Maxwell, & Hogan, 
2004; Lee et al., 2013; Salazar, Poon, & Nair, 2007). One of the main causes of medication non-
compliance as stated by patients is the complexity of drug regimen (Jimmy & Jose, 2011). 
Corsonello et al. (2009) suggested that patients are often confused by the drug regimen 
(Corsonello, 2009). Fulmer et al (2001) reported that older adults usually take as many as 5-10 
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medications daily leading to confusion about which medications to take when (Fulmer, Kim, 
Montgomery, & Lyder, 2001). In a systematic review by Rollason et al. (2003) it was found that 
among patients taking 4 or more medications the rate of patient non-adherence was as high as 
35% (Rollason & Vogt, 2003). In another study by Rottlaender et al. (2007), it was found that 
polypharmacy with more than four pills a day significantly decreased medication compliance 
(Rottlaender, Scherner, Schneider, & Erdmann, 2007). 
Increased healthcare costs: Polypharmacy significantly contributes to healthcare costs both to 
the patient and the healthcare system. A retrospective cohort study found that polypharmacy was 
associated with a 30% increase in total medical costs (Akazawa, Imai, Igarashi, & Tsutani, 
2010). Another study conducted in Sweden reported that those taking 5 or more medications had 
a 6.2% increase in prescription drug expenditure and those taking 10 or more medications had a 
7.3% increase in prescription drug expenditure (Hovstadius & Petersson, 2013). Health plans are 
at high risk for significant costs associated not only with increased drug utilization patterns due 
to polypharmacy but also are at risk of costs associated with the potential health complications 
due to mixing many medications (Marabella, 2015).  
Morbidity and mortality: The risk of drug toxicity or overmedication increases with use of 
multiple medications at high dosages. Not only do sicker patients get multiple medications, they 
usually get them at higher doses (Rosack, 2003). It has been found that antipsychotic 
polypharmacy results in patients being prescribed higher doses of antipsychotic medication 
(Lelliott et al., 2002). Further, the likelihood of death is directly proportional to the number of 
medications a person with a psychiatric disability is taking, even when controlled for underlying 
diseases (NASMHPD, 2001; Werder & Preskorn, 2003). Increased risk of mortality has been 
observed in patients with schizophrenia with the use of more than one antipsychotic medication 
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concurrently (Waddington, Youssef, & Kinsella, 1998; Maher, Hanlon, & Hajjar, 2013; 
NASMHPD, 2001). 
 Furthermore, polypharmacy has been known to lead to other negative 
consequences like cumulative toxicity, medication errors, impairment of functional status, and 
cognitive impairment. 
Further concerns of long-term pediatric psychotropic polypharmacy:  
Research has consistently shown an increase in the number of children prescribed various 
classes and combination of psychotropic medications (Pidano, Meyers, & Honigfeld, 2011; 
Naylor et al., 2007; Martin, Van Hoof, Stubbe, Sherwin, & Scahill, 2003; Zito, 2000). The use of 
psychiatric polypharmacy in children has been on the rise during the past decade. This is 
alarming because not only are the children at high risk of the potential negative consequences 
associated with polypharmacy as discussed in the previous section but also there is limited 
scientific evidence for understanding the immediate or long-term effects of polypharmacy on a 
child’s growth and development. Many of the medications used in pediatric population have not 
been studied or approved for use with children (Magellan Health, 2013). Often these medications 
are prescribed “off-label”, meaning for a mental disorder or age group apart from the one for 
which they have been approved by the Food and Drug Administration (FDA). Drugs are usually 
tested in isolation against placebo or suitable comparator, so enough data is not available on 
which drug combinations may be harmful. Further these clinical trials are usually conducted in 
adult population and exclude children and adolescents, thus overall pediatric clinical evidence is 
hard to come by. Among all the concerns in children and adolescents regarding polypharmacy 
the most crucial is that of increased risk of adverse events (Zonfrillo, Penn, & Leonard, 2005). 
Numerous examples of drug-drug interactions have come forward in this population. For 
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example, concurrent use of methylphenidate and clonidine has led to sudden death of 4 children. 
Death of a 9 year old on fluoxetine, promethazine, methylphenidate and clonidine due to 
overdose has been reported (Cantwell, Swanson, & Connor, 1997; Popper, 1995; FDA, 2010). 
Serotonin syndrome leading to high levels of serotonin accumulation in the body can result when 
a youth receives two or more medications with serotonergic properties. Further, the safety of 
some monotherapy has been questioned, example antipsychotics have been found to cause 
weight gain and metabolic disorders in children and use of anti-depressants has resulted in 
development of suicidal ideation in some children. Thus if monotherapy can cause such harm it 
certainly raises questions regarding safety of polypharmacy in children. 
Ever widening gap between guidelines and practice: 
According to the American Academy of Child and Adolescent Psychiatry (AACAP) 
“little data exists to support advantageous efficacy for drug combinations,” and, “current clinical 
‘state-of-the-art’ supports judicious use of combined medications, keeping such use to clearly 
justifiable clinical circumstances” (AACAP, 2001; Zonfrillo, Penn, & Leonard, 2005). Currently, 
only a few psychiatric drugs are approved by the US Food and Drug Administration for use in 
children, all other usage of psychiatric medications in children is off-label. Clinical guidelines 
recommend monotherapy as the preferred therapy in psychiatric practice. 
Despite these recommendations the use of psychiatric polypharmacy is quite common in clinical 
practice. The overall prevalence of psychiatric polypharmacy varies between 13-90% depending 
on the clinical setting and study design (Taylor, 2002; De las Cuevas & Sanz, 2004; Stahl, 2002). 
Up to 33% of patients visiting outpatient psychiatry department have been found to be on three 
or more psychotropic medications (Mojtabai & Olfson, 2010; Shrivastava, Kukreja, Kalra, & 
Shah, 2013). A significant decline in the use of psychotropic monotherapy and increase in use of 
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polypharmacy has been observed in the inpatient setting during the last few decades. A review 
by Rittmannsberger et al (2002) reported the use of monotherapy in 48% patients before 1980, 
which declined to 31% between the years 1981-1990 and further declined to 20% in 1991-2000 
(Rittmannsberger, 2002). A study from NIMH shows that prescription of 3 or more medications 
at discharge increased from 5% in 1974 to 40% in 1995 (Presborn & Flockhart, 2006). 
Psychiatric polypharmacy is not only widespread in adult population, but also increasingly seen 
in children and adolescents. The prevalence of psychotropic polypharmacy has increased by two 
to seven folds in this population. Overall, the estimated prevalence of psychiatric polypharmacy 
ranged from about 14% among children insured by Medicaid to about 73% among children in 
foster care. In the study by Zito et al among the children in Texas foster care the prevalence of 
multiclass psychotropic medication use was found to be as high as 72.5% (Zito et al., 2008). 
Prevalence estimates and definitions of psychotropic polypharmacy vary with study design and 
population. Table 2 summarizes the prevalence of psychotropic polypharmacy in pediatric non-
foster population.  
Table 2: A summary of prevalence of psychotropic polypharmacy in the United States pediatric 
population 
Study Population Definition of 
polypharmacy 
Prevalence 
Pediatric Non-Foster Population 
Chen, Patel, 
Sherer, & 
Aparasu, 2011 
Medicaid population: California, 
Illinois, New York and Texas, 
children age 6-18 years of age 
≥ 2 psychotropic 
medications from the same 
or different categories, 
receiving ≥14, ≥30, ≥60, 
and ≥90 consecutive days 
of overlapping prescription 
fills 
≥ 14 days: 
28.8% 
≥ 30 days: 
27.2% 
≥ 60 days: 
20.9% 
≥ 90 days: 
17.7% 
Comer, 
Olfson, & 
Mojtabai, 
2010 
National Ambulatory Medical 
Care Surveys (children and 
adolescents) 1996-2007 
(N=3466) 
Multiclass psychotropic 
treatment during a 
physician office visit 
19% 
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McIntyre & 
Jerrell, 2009 
South Carolina Medicaid , 
children and adolescents with 
major depression from 1996-
2005 (N=1544) 
Physician who prescribed  
≥ 2 psychotropic 
medications 
1996: 6.7% 
2005:41.6% 
Duffy et al., 
2005 
Cross-sectional data reported for 
youths ages 2–17 by the 
American Psychiatric Practice 
Research Network of psychiatric 
patients and treatment for 1997–
1999 (N=392) 
Concurrent use of ≥ 2 
psychotropic medications 
52% 
DosReis et al., 
2005 
Youth age < 20 years enrolled in 
Medicaid or SCHIP in 2 states 
in 1999 (N=40856 and 
N=235093) 
Use of ≥ 2 psychotropic 
medication classes within 
same month 
28%-30% 
Martin, Van 
Hoof, Stubbe, 
Sherwin, & 
Scahill, 2003 
Children and adolescents 
ranging in age from newborn to 
18 years enrolled in Connecticut 
Medicaid managed care for 
1998-1999 (N=196549) 
Claims for medications 
from ≥ 2 psychotropic 
drug classes during 7-day 
interval after index 
prescription 
13.6% 
Olfson, 
Marcus, 
Weissman, & 
Jensen, 2002 
U.S. civilian, 
noninstitutionalized population 
NMES 1987 and MEPS 1996 
Use of ≥ 2 psychotropic 
medication classes during 
1 year period 
1987: 3% 
1996: 23% 
Rappley et al., 
2002 
Pharmacy claims data (< 3 years 
age), ADHD patients Michigan 
Medicaid 1995-1996 
Use of ≥ 2 psychotropic 
medications filled on the 
same day, or within 7 days 
of each other over the 15 
months 
35% 
Bhatara, Feil, 
Hoagwood, 
Vitiello, & 
Zima, 2002 
National Ambulatory Medical 
Care Surveys (children <18 
years of age) 1993-1998 
% visits with concomitant 
psychotropic prescription 
1993-94: 
4.78% 
1995-96: 
10.79% 
1997-98: 
24.70% 
 
Pediatric Psychotropic Polypharmacy and Medicaid Psychotropic Drug Utilization Review 
Due to the growing concerns of potential inappropriate use of psychotropic medications 
in children and adolescents a number of measures have been implemented by State Medicaid 
agencies with the help of CMS (Centre for Medicare and Medicaid Services). Medicaid Drug 
Utilization Review (DUR) programs have been employed by each of the 50 states, which employ 
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a variety of techniques to intensify the oversight of prescribing of the psychotropic medications 
in children, especially for children in foster care (Medicaid and CHIP Payment and Access 
Commission, 2015). According to the Medicaid Drug Utilization Review Comparison/ Summary 
Report of 2014, forty-one states (82%) have programs in place to either manage or monitor the 
appropriate use of psychotropic medications in children. Thirty-six states have programs that 
monitor all children, not just the children in foster care. In general, every state has pre-
programmed edits to screen the appropriate use of psychotropic medications in children, a few 
examples of such targeted edits are: preauthorization edits for younger children <5 years of age 
which requires a manual review of prescription request by a panel of experts; therapeutic 
duplication edits to avoid duplication of medications from the same therapeutic class or with 
same pharmacological action; preauthorization edits to reduce the rates of polypharmacy and 
specific edits for prescribing and monitoring guidelines for use of psychotropic medications in 
the children in foster care. A few states also have data registries that analyze the prescribing of 
psychotropic drugs and provide physician feedback and training (CMS, 2014).  
 
The Effect of Medicaid Psychotropic Drug Utilization Review on Pediatric Psychotropic 
Polypharmacy 
At least 36 states have implemented programmed edits to manage or monitor the use of 
psychotropic polypharmacy and off-label use of psychotropic medications in children and 
adolescents in foster Care. The STAR Health Psychotropic Medication Utilization Review 
(PMUR) implemented by the state of Texas is one such program. The Texas child welfare 
system released a “best practices” guide to ensure appropriate use of psychotropic medications 
for children in foster care in February 2005. These quality metrics have been updated in 2007, 
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2010 and 2013 (DFPS, 2016). In 2014, the Texas Health & Human Services Commission 
(HHSC) modified Section 8.1.21.6 of its Uniform Managed Care Terms & Conditions and made 
the PMUR a mandatory process for Medicaid Managed Care Organizations (MCOs). The PMUR 
involves monitoring of “guideline non-concordant” prescribing of psychotropic medications in 
children, specifically focusing on the use of psychotropic polypharmacy (Psychotropic 
Medication Utilization Parameters, 2016). Since the introduction of “best practices” in 2005 and 
the later updates in PMUR, the prescribing of psychotropic medications in the foster care 
population has been on a downward trend. Based on the available data, the percentage of foster 
children receiving any psychotropic medications for ≥ 60 days peaked in 2004 at 29.9% and at 
the end of year 2009 had dropped to 19.7%. The rate of children in foster care who experienced 
class polypharmacy has dropped by nearly 75%, and the percentage receiving 5 or more 
psychoactive medications is down by nearly 80% (Texas Health and Human Services 
Commission, 2010). This reduction in the rate of prescribing psychotropic medications and 
psychotropic polypharmacy is largely attributable to the use of PMUR.  
 
The need to further address inappropriate use associated with psychotropic polypharmacy and 
the limitations of Medicaid psychotropic Drug Utilization review 
There are a number of limitations to the current Medicaid Drug Utilization review 
parameters. First of all, these parameters are only used to monitor guideline non-concordant 
prescribing which result from individual providers’ knowledge and attitudes. The whole 
emphases of these parameters are on the non-concordant behavior of a single individual provider. 
In these settings once the individual provider who is frequently involved in out-of-parameter 
prescribing has been identified, peer-to peer interview is conducted reasoning such behavior and 
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corrective action is taken to avoid future repetition (DFPS, 2016). In this approach, the out-of-
parameter prescribing behaviors are handled one by one, and there is no investigation or 
modification of the environment from which the behavior originated. These DURs and 
intervention programs fail to acknowledge that some out-of-parameter uses, especially 
therapeutic duplication and polypharmacy, could arise from poor communication among 
providers rather than due to the individual’s out-of-parameter practice. Second, due to the 
complexity of disorders among children and adolescents, they usually see multiple providers as 
compared to their peers. As a result they may have medications prescribed from several sources 
which can lead to therapeutic duplication and polypharmacy. Third, the current parameters do 
not take in to consideration the effect of peer influence. Past studies have shown that the 
physicians’ prescribing behavior can be influenced by his/her peers in addition to their own 
personal preferences. Lastly, there is a lot of variation in the parameters specifically with respect 
to the definition of duration of psychotropic polypharmacy. Some parameters define 
polypharmacy on the basis of use of multiple psychotropic medications for more than 60 days 
while others define it based on use of multiple psychotropic medications for more than 90 days 
(PSYKES, 2011; Psychotropic Medication Utilization Parameters, 2016).  
  
 The potential barriers of expanding PMUR from foster children to all Medicaid covered 
Pediatric Population 
Although the PMUR parameters are specifically targeted for the foster care population, 
there is some overlap between the physicians treating the children in foster care and those 
treating the general Medicaid children. So there is a potential possibility that these parameters 
are also being implemented in the psychiatric care of the general Medicaid children. However, 
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there are certain barriers in the expansion of PMUR from foster care to the general Medicaid 
population. About 80% of the Texas Medicaid population is enrolled in Medicaid managed care 
as of August 2014. Within Medicaid managed care in Texas there currently are three 
comprehensive programs: STAR (low-income families, children, pregnant women, and some 
former foster care youth), STAR+PLUS (mostly adults 21 years and older), and STAR Health 
(Foster Care). Of these only the STAR health program monitors use of psychotropic medications 
using the PMUR medication utilization parameters (Texas Health and Human Services 
Commission, 2015). STAR Health forms a very small share (only 0.8%) of the total Medicaid 
population. There are children who do not qualify for STAR Health and whose psychotropic 
medication usage is not monitored in the system. These include the children who are placed in 
Texas through an Interstate Compact on the Placement of Children (ICPC), children who are 
dual eligible for Medicaid and Medicare, and general Medicaid children population (Barillas, 
2009). 
The STAR Health program is the most comprehensive managed care plan under Texas Medicaid. 
The population enrolled in STAR Health is considered as a high-risk population with greater 
medical and behavioral needs than most children in Medicaid. STAR Health clients receive 
medical, dental, vision, and behavioral health benefits, including unlimited prescriptions. The 
program includes access to an electronic health record called the Health Passport, which contains 
a history of each child's demographics, doctor visits, immunizations, prescriptions, and other 
pertinent health-related information. The program also includes a 7-days-per-week, 24-hours-
per-day nurse hotline for caregivers and DFPS caseworkers. Use of psychotropic medications is 
carefully monitored in this population. STAR health has a large Human resource in terms of 
caseworkers and caregivers who help in the coordination of care delivered; facilitation of 
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communication between providers; set up follow up appointments and implementation of plan of 
care. They further help with easy outreach to the providers involved in the provision of 
healthcare to the enrolled children. The resources invested in STAR Health are more than that in 
any of the other plan in the Texas Medicaid managed care (Texas Health and Human Services 
Commission, 2015). The lack of resources in other managed care programs become a potential 
barrier for the implementation PMUR to all Medicaid covered pediatric population. The paucity 
of funding and manpower leads to more difficulty in outreaching the providers involved in 
provision of care. The medical affairs of most MCOs rely on a few physicians and pharmacists to 
manage all diseases and treatments covered by the plan. They only have the capacity to review 
and reach out to a small fraction among thousands of contracted providers. Not every MCO has 
the financial and human resource available to conduct this review process.  
 
Physicians Social Network and Prescribing behavior 
Physicians are not isolated individuals but part of a social structure who may be 
influenced. It is seen that clusters of physicians usually adopt the behavior of their peers and 
opinion leaders (most influential physician). This influence is exerted due to a variety of reasons 
including day-to-day interactions, referrals, and shared patients (Gallo, 2012). If there is a strong 
peer effect in the prescribing of psychotropic medications to children, targeting and changing the 
prescribing behavior of guideline non-concordant prescribers could lead to a cascading effect in 
guideline diffusion among other physicians within the network, resulting in increased 
concordance with guidelines. Furthermore, due to complexity of mental disorders, patients 
usually see multiple providers. Thus, poor communication and collaboration among the patients’ 
care team can lead to multiple prescriptions of same class of medications (polypharmacy). 
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Efficient channels of communication and collaboration among physicians are recognized as a 
catalyst to improved patient care (Uddin, Hossain, Hamra, & Alam, 2013). It allows input from 
multiple providers caring for the same patient, which produces decisions based on complete 
information, which in turn lead to better patient outcomes.  
Social Network Analysis (SNA) is a set of theories and techniques used to understand 
how social relationships (e.g., friends/peers, advice seeking, and reputation) influence behaviors 
(Gesell, Barkin, & Valente, 2013). SNA is commonly used to study relationships between 
individuals and communities as they interact with each other (Valente, Gallaher, & Mouttapa, 
2004). In the healthcare domain, social network analysis has been used in different settings, for 
example to study collaboration among healthcare professionals in specific healthcare 
environments, to understand the impact of team structure on quality of care. Studies have been 
conducted using SNA to analyze health care networks, addressing topics such as the exchange of 
clinical advice, the diffusion of pharmaceutical use, or organizational performance and cost-
efficiency (Keating, Ayanian, Cleary, & Marsden, 2007; Christakis & Fowler, 2010; Iyengar, 
Van den Bulte, & Valente, 2011; Barnett et al., 2012). The studies on diffusion of new 
pharmaceuticals have used SNA to analyze the influence of opinion leaders or key action leaders 
on daily prescribing practices (Iyengar, Van den Bulte, Eichert, & West, 2011). Social network 
analysis has been used to study the effect of patient sharing networks on quality of care, cost of 
care, hospital outcomes (Mundt et al., 2015; Pollack, Weissman, Lemke, Hussey, & Weiner, 
2012; Uddin, Hossain, Hamra, & Alam, 2013). Lately a few studies have also used Social 
network analysis to study the effect of patient sharing networks on multiple-provider prescribing 
of drugs and for examination of prescribing error rates (Creswick & Westbrook, 2015; Ong et al., 
2015).  
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SNA examines physicians’ behaviors in the context of their professional social structure 
(network) where they communicate, collaborate, compete and exert influences on each other. 
The measures of SNA that will be used in the current study include cohesion, structural 
equivalence and care-density. The two contagion mechanisms, cohesion (direct communication) 
and structural equivalence (comparison) will be used to study peer influence. Cohesion refers to 
the actors (physicians) being directly connected in a network. In the healthcare context, cohesion 
implies that physicians acquire information about their peers behavior or attitudes through direct 
communication. On the other hand the peer influence through structural equivalence is based in 
part on the competition that exists between people when they evaluate new situations. Burt and 
others (Burt, 1987; 2010; Fujimoto & Valente, 2012) have reported that “the more similar ego's 
and alter's relations with other persons- the more that alter could substitute for ego in ego's role 
relations, and so the more intense ego's feeling of competition with the alter, the more likely that 
ego will quickly adopt any innovation”. Further, the effect of patients’ care team interactions will 
be studied using the care-density measure. Care-density corresponds to the care team’s 
cohesiveness which is theoretically a representation of effective collaboration and 
communication between the patient’s care teams (Pollack, Weissman, Lemke, Hussey, & 
Weiner, 2012; Pollack, Lemke, Roberts, & Weiner, 2015).  
SNA provides a unique perspective to understand the underlying reasons of prescribing 
decisions and medication errors. Therefore, in this study we use measures of Social Network 
Analysis to examine the role of inter-provider relationships (communication, collaboration and 
peer influence) in guideline-non-concordant use of psychotropic medications.  
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2.2 Rationale and Significance 
Psychotropic polypharmacy refers to the prescription or administration of a) two or more 
medications to treat the same mental health condition or b) two or more psychotropic 
medications of the same drug class. Psychotropic polypharmacy is a high priority quality concern 
especially in children and adolescents as there are only a limited number of clinical trials 
evaluating the effectiveness, risks and long-term effects of using two or more psychiatric drugs 
in combination. The major concerns associated with the use of polypharmacy include: adverse 
drug reactions, drug-drug interactions, cumulative toxicity, medication errors, patient non-
compliance and patient morbidity and mortality (Kingsbury, Yi, & Simpson, 2001; NASMHPD, 
2001; Werder & Preskorn, 2003). Despite the risks and concerns, there is an increase in the trend 
of psychotropic polypharmacy in children and adolescents.  In a national study of office-based 
psychotropic prescription in children and adolescents with a psychiatric diagnosis, the rate of 
polypharmacy increased from 22% to 32% over 12 years. In a recent study of Medicaid claims in 
one state, 38% of youth on any psychotropic medication were prescribed more than one drug. 
As a result of the growing concerns of psychotropic polypharmacy in children and 
adolescents the State Medicaid agencies with the help of CMS employed Drug Utilization 
Review programs in all the 50 states, which employ a number of measures to intensify the 
oversight of prescribing of the psychotropic medications in this population. Psychotropic 
Medication Utilization Review (PMUR) for children in foster care is one such measure 
developed by the Texas HHSC, which involves monitoring of “guideline non-concordant” 
prescribing of psychotropic medications in children, specifically focusing on the use of 
psychotropic polypharmacy. Although these guidelines and utilization review system is 
specifically targeted for the foster care population, there is some overlap between the physicians 
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treating the children in foster care and those treating the general Medicaid children. So it is 
highly likely that these parameters are also being implemented in the psychiatric care of the 
general Medicaid children. Many managed care organizations (MCOs) have also started 
implementing criteria similar to PMUR for monitoring appropriate use of psychotropic 
medications in children.  
However, there are a number of limitations to these psychotropic medication utilization 
parameters. First of all, these parameters are only used to monitor guideline non-concordant 
prescribing which result from individual providers’ knowledge and attitudes. These DURs and 
intervention programs fail to acknowledge that some out-of-parameter uses, especially 
polypharmacy, could arise from poor communication among providers rather than due to the 
individual’s out-of-parameter practice. Second, due to the complexity of disorders among 
children and adolescents, they usually see multiple providers as compared to their peers. As a 
result they may have medications prescribed from several sources, which can lead to therapeutic 
duplication and polypharmacy. Third, the current parameters do not take in to consideration the 
effect of peer influence. Past studies have shown that the physicians’ prescribing behavior can be 
influenced by his/her peers in addition to their own personal preferences.  
Physicians seldom practice as isolated individuals; they are a part of a social structure 
that involves clusters of physicians treating a certain set of patients over a period of time. It is 
seen that these clusters of physicians usually adopt the behavior of their peers. They can be 
influenced by their peers due to a variety of reasons including day-to-day interactions, referrals, 
and shared patients. If there is a strong peer effect in the prescribing of psychotropic medications 
to children, targeting and changing the prescribing behavior of guideline non-concordant 
prescribers could lead to a cascading effect in guideline diffusion among other physicians within 
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the network, resulting in increased concordance with guidelines. Furthermore, patients with 
mental disorders usually visit multiple providers. Poor communication and collaboration among 
these providers can lead to multiple prescriptions of same class of medications (polypharmacy). 
Social Network Analysis (SNA) is a set of theories and techniques used to understand 
how social relationships influence behaviors. SNA examines physicians’ behaviors in the context 
of their professional social structure (network) where they communicate, collaborate, compete 
and exert influences on each other. SNA provides a unique perspective to understand the 
underlying reasons of prescribing decisions and medication errors. It has the potential to address 
limitations of the existing PMUR program and to improve the quality of treatment for Medicaid 
enrolled children with mental disorders. Therefore, the objective of the proposed research is to 
examine the role of inter-provider relationships (communication, collaboration and peer 
influence) in guideline-non-concordant use of psychotropic medications using measures of social 
network analysis. The current study would inform the feasibility of designing and implementing 
social network theory guided interventions to accelerate guideline diffusion and reduce 
inappropriate use due to poor communication among physicians. 
 
2.3 Innovation  
 The current study uses the Texas Psychotropic Medication Utilization Review (PMUR) 
guidelines and the measures of Social Network Analysis to study the use of psychotropic 
polypharmacy (guideline non-concordant use) in children and adolescents enrolled in the Texas 
Children’s Health Plan (TCHP). The TCHP is a unique Health Maintenance Organization 
(HMO) created just for children. TCHP is an administrator for the State Children’s Health 
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Insurance Program (CHIP) and STAR/Medicaid managed care programs making TCHP the best 
source of data to study the implementation of the PMUR guidelines.  
Previous studies on psychotropic polypharmacy are mostly cross-sectional evaluations on 
prescribing of psychotropic medications at a single point of time and often have not considered 
the overlapping period of concurrent use while defining psychotropic polypharmacy. Some 
longitudinal studies that have taken into consideration the duration of overlap have inconsistent 
definitions for the period of overlap. None of these studies have used the State mandated 
Medicaid drug utilization review guidelines for defining psychotropic polypharmacy. The 
current study uses the PMUR parameters developed by HHSC for the children in Texas foster 
care to define the “guideline non-concordant” use of psychotropic medications, specifically 
focusing on psychotropic polypharmacy. 
Further, the current PMUR guidelines emphasize solely on the non-concordant behavior 
of a single individual provider for review of potential inappropriate use and do not take in to 
consideration the role of inter-provider relationships (communication, collaboration and peer 
influence) on such non-concordant behavior. Past studies have shown that physicians’ peers and 
opinion leaders can influence prescribing decisions. Also, involvement of multiple physicians in 
the provision of care can lead to therapeutic duplication due to poor communication and 
collaboration between physicians. In view of these limitations the current study proposes to use 
the theories and techniques of Social Network Analysis to understand how peer-influence, 
communication and collaboration between physicians affects the adoption of the guidelines. 
SNA will help understand the underlying reasons of prescribing decisions. Social Network 
analysis has been used previously to study the effect of patient sharing networks on prescribing 
practices and diffusion of new pharmaceuticals. However, none of these studies have used SNA 
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to study the effect of patient sharing networks on use of psychotropic polypharmacy (guideline 
non-concordant use).  
To our knowledge this is the first study to use Social Network Analysis to understand the 
role of inter provider relationships in guideline non-concordant use of psychotropic medications. 
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Abstract 
BACKGROUND:  Psychotropic polypharmacy (PP) is highly prevalent in the treatment of 
pediatric mental disorders. However, literature studying the risk factors associated with use of PP 
is scarce, especially with respect to whether risk factors differ between patients treated by single 
prescriber (SP) versus multiple prescribers (MP). 
OBJECTIVE: To advance the understanding of the prevalence of and risk factors associated 
with long-term multiclass psychotropic polypharmacy (PP) among children and adolescents with 
mental/behavioral disorders in a Texas Medicaid population. 
METHODS: A retrospective cross-sectional study was conducted using the 2013-2015 
administrative claims data from a Medicaid Managed Care Organization (Texas Children’s 
Health Plan). The study included individuals: a) ≤18 years of age, b) diagnosed with a mental 
disorder, and c) had at least one pharmacy claim of psychotropic medication during the study 
period. Based on the number of prescribers involved in the treatment the individuals were 
categorized into two groups: a) single prescriber (SP) and b) multiple prescribers (MP). PP was 
defined as the receipt of ≥ 2 psychotropic medications from different drug classes concurrently 
for 60 days or more. Two separate logistic regression models (SP and MP) were conducted to 
determine associations between PP and patients demographics, diagnosis, clinical complexity 
and prescriber characteristics. The Farilie decomposition method (extension of Blinder-Oaxaca 
[BO] decomposition) was further applied to test the differences in receipt of psychotropic 
polypharmacy between patients treated by PCPs vs those treated by specialists 
RESULTS: A total of 24,147 children and adolescents met the inclusion criteria. The prevalence 
of multiclass PP was 20.09%. Other significant factors associated with PP were patient race and 
diagnosis of bipolar disorders and depression, as well as the number of mental disorders 
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diagnosed and number of prescribers involved in treatment (MP group only). The most 
prominent factor associated with the receipt of psychotropic polypharmacy was the involvement 
of specialist in the treatment. Patients with a specialist involved in the treatment had 5.3 times 
and 3.6 times higher likelihood of receiving PP in the SP and MP groups respectively (SP: 
OR=5.324; 95% CI 4.620-6.136 & MP: OR=3.571; 95% CI 3.199-3.985).  Other factors 
positively associated with psychotropic polypharmacy were being a male, Caucasian race, 
diagnosis of ADHD and bipolar disorder(s). The number of mental/behavioral disorder 
diagnosed and the number of providers involved in treatment were unique predictors positively 
associated with polypharmacy in the multiple prescriber group. The Farilie decomposition 
analysis estimated that the observed need factors explained only approximately 25% of the 
difference in the receipt of PP between patients seen by PCPs and specialists within both SP and 
MP groups. 
CONCLUSIONS: The most prominent factor associated with PP was involvement of a 
specialist in the treatment of mental/behavioral disorders. Only a quarter of the difference 
between PCPs and specialists with respect to prescription of PP was explained by observable 
need factors, underscoring the drastically different prescribing habits between PCPs and mental 
health specialists, and the complex implications of pediatric psychotropic polypharmacy. 
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INTRODUCTION 
Clinical guidelines recommend monotherapy as the preferred therapy in the treatment of 
mental/behavioral disorders. According to the American Academy of Child and Adolescent 
Psychiatry, data supporting advantageous efficacy for drug combinations is scarce and 
contemporary clinical evidence supports cautious use of psychotropic drug combinations limiting 
such use to clinically justifiable circumstances.1 Simultaneous use of multiple psychotropic 
medications either from same drug class (within-class psychotropic polypharmacy) or from 
different drug classes (multiclass psychotropic polypharmacy) has been associated with a 
number of concerns including adverse events2,3, drug-drug interactions4,5, non-adherence6, 
higher-healthcare costs7, morbidity and mortality8,9. These concerns are further heightened in 
children and adolescents as there is limited scientific evidence for understanding the immediate 
and/or long-term effects of psychotropic polypharmacy on child’s growth and development. 
Also, many psychotropic medications are used “off-label” in this population due to exclusion of 
this population from clinical trials.10 Despite these recommendations and concerns the use of 
psychotropic polypharmacy is quite common in clinical practice.11-13 
Overall the prevalence of psychotropic polypharmacy ranges from 14% to 73% among 
pediatric population depending upon the age groups, study designs, data sources and clinical 
settings.14-21 Most of the studies that estimated the prevalence of psychotropic polypharmacy 
have used cross-sectional definitions of polypharmacy measured at a single point of time or 
within a certain time frame and have been usually based on short-term overlap of medications. 
However, there are instances where short-term polypharmacy is clearly appropriate or even 
necessary such as acute amelioration while awaiting the effect of another medication, treating 
distinct comorbid conditions, boosting the efficacy of primary treatment and treatment of 
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intervening phases of an illness.22 The studies that have used long-term (≥60 days) definition of 
psychotropic polypharmacy have mostly measured within-class polypharmacy only.23 A study by 
Chen et al, has used long-term overlap to define both multiclass and within-class psychotropic 
polypharmacy but they did not study the risk factors associated with the polypharmacy.14 One 
study that determined the risk factors associated with multiclass psychotropic polypharmacy 
used only a 30-day overlap criteria and the population was limited to patients with Autism 
Spectrum Disorders.24 Further, it has been established by previous studies that one of the 
prominent factors associated with polypharmacy is visiting multiple physicians, however in our 
understanding there has been no study that has attempted to understand whether risk factors 
associated with psychotropic polypharmacy differ among patients with single prescriber involved 
in treatment and those with multiple prescribers involved in treatment.       
Therefore, the objective of this study was to advance the understanding of the prevalence 
of and risk factors associated with long-term multiclass psychotropic polypharmacy among 
children and adolescents with mental/behavioral disorders in a Texas Medicaid population. 
Additionally, estimates for patients with single prescriber involvement and multiple prescriber 
involvement were obtained to understand whether risk factors associated with psychotropic 
polypharmacy differ among these groups. 
METHODS  
Study Design and Data Source:  
This is a retrospective cross-sectional study conducted using the administrative claims 
data from Texas Children’s Health Plan (TCHP) for the period of July 1, 2013 to June 30, 2015. 
A pre-sampled data of only those children and adolescents who were ever diagnosed with 
mental/behavioral disorders identified using ICD 9-CM codes (Appendix A) and who had 
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continuous enrollment throughout the study period was obtained from TCHP. TCHP is the 
nation’s first health maintenance organization (HMO) created just for children. It functions as an 
administrator for the State Children’s Health Insurance Program (CHIP) and STAR/Medicaid 
managed care programs through a contract with the state Medicaid administrator. TCHP has 
more than 400,000 members and over 1,100 primary care physicians, 3,200 specialists and 60 
hospitals that provide service and patient care to these members. Of the 400,000 members 68% 
are Hispanics, 16% are Caucasians, 9% are African Americans and the rest are other racial/ethnic 
groups. The TCHP data provides information on outpatient medical claims, and pharmacy 
claims. The data also includes information on patient characteristics e.g. patient age, gender, 
race, and physician characteristics e.g. gender, and specialty. The data is de-identified in 
accordance with the Health Insurance Portability and Accountability Act (HIPAA) standards. 
The study was reviewed and approved by the University of Houston Institutional Review Board. 
Study Sample:  
The study sample consisted of all children and adolescents aged 0 to 18 years who were 
continuously enrolled in the Texas Children Health Plan, were diagnosed with a 
mental/behavioral disorder and had at least one pharmacy claim of psychotropic medication 
during the study period. Psychotropic medications included: drugs for attention-deficit 
hyperactivity disorder such as stimulants, non-stimulant (atomoxetine), alpha-agonists 
(guanfacine, clonidine); anti-depressants (selective serotonin norepinephrine reuptake inhibitors, 
serotonin reuptake inhibitors, and tricyclic antidepressants); antipsychotic agents (first and 
second generation); lithium; anticonvulsant mood-stabilizers (such as divalproex, oxcarbazepine, 
carbamazepine, lamotrigine), and anxiolytics (such as hydroxyzine and benzodiazepines).  
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The identified individuals were then categorized into two groups based on the number of 
prescribers involved in the treatment as: a) single prescriber involved in treatment and b) 
multiple prescribers involved in treatment. 
Measures:  
Within each of these study groups the primary outcome of interest was whether an 
individual had at least one episode of multiclass psychotropic polypharmacy measured as a 
binary variable (1: Yes, 0: No). Multiclass psychotropic polypharmacy episode was defined as 
the receipt of 2 or more psychotropic medications from different drug classes concurrently for ≥ 
60 days, with no gaps in polypharmacy treatment. The 60-day overlap criterion was used, as it is 
the most commonly used cutoff used to define polypharmacy, it avoids misclassifying instances 
of cross-titration as polypharmacy.23, 24 Patients who received psychotropic medications but did 
not have a polypharmacy episode at any time during the study period were classified as non-
polypharmacy cases. Episodes of treatment were identified using the prescription fill date and the 
days’ supply information available from the pharmacy claims. Before measuring the episodes, 
overlapping days’ supply for the same medication were carried forward assuming that the patient 
finished the current prescription before starting on the refill prescription. Gaps in fills of the 
same medication of ≤ 15 days were allowed and adjusted in the calculation of the overlap. 
Further, the overlap was defined by drug class and not specific medications within class, so it 
was not necessary for a single medication within a class to overlap by ≥ 60 days with a particular 
medication in another class. Only unique combinations of drug classes of at least 60 days were 
considered.  
         Among patients receiving multiclass psychotropic polypharmacy the secondary outcomes 
of interest were the duration of polypharmacy episode and the number of polypharmacy episodes 
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during the study period. Duration of polypharmacy episode was calculated as the number of days 
from the first date that ≥2 psychotropic medications from different drug classes were received 
concurrently to the last date that such concurrent medications were received with no gaps in 
polypharmacy treatment. Number of polypharmacy episodes was calculated as patients could 
have more than one multiclass psychotropic polypharmacy episode during the study period if 
they initiated, discontinued and reinitiated on polypharmacy. 
Statistical Analysis:  
Descriptive statistics, including frequencies, mean (± SD) and median, were used to 
characterize patient characteristics, number and duration of polypharmacy episodes. Within each 
of the study groups the differences between non-polypharmacy patients and those experiencing 
polypharmacy were analyzed using t-tests and Chi-square tests. A-priori significance level of 
p<0.05 was chosen for all comparisons.  
Logistic regression was used to determine associations between polypharmacy and 
independent variables of interest. The independent variables considered include patient age, sex, 
race; number of mental/behavioral disorders diagnosed; type of mental/behavioral disorder 
diagnosed; number of prescribers involved in treatment and whether a specialist was involved in 
treatment. Two separate multivariable models were conducted 1) single-prescriber involved in 
the treatment and 2) multiple-prescriber involved in treatment.  
Post-hoc analysis: 
        The Farilie decomposition method (extension of Blinder-Oaxaca [BO] decomposition) was 
used to test the difference in receipt of psychotropic polypharmacy between patients treated by 
PCPs vs those treated by specialists.25-28 The aim was to understand the contribution of 
predisposing (patient age, sex and race) and need factors (number of mental/behavioral disorders 
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diagnosed; type of mental/behavioral disorder diagnosed; number of prescribers involved in 
treatment) used in the multivariable model towards explaining the difference between PCP and 
specialist practice with respect to psychotropic polypharmacy. In the Fairlie’s nonlinear method, 
a 1:1 matching of observations between PCPs and specialists was done to identify the 
contribution of each of the predisposing and need factors. A random subsample of observations 
was selected from the majority group (PCPs) and matched to the minority group (specialists), as 
the number of observations between PCPs and specialists was not equal. The matched sample 
was then used to estimate the contribution of each factor towards explaining the difference in the 
receipt of polypharmacy. A 1000 random subsamples of PCPs were used to eliminate the bias 
due to subsampling. The final decomposition was an average of these subsamples. Separate 
analysis was conducted for the single prescriber group and the multiple prescriber group. 
Sensitivity analysis: 
Sensitivity analysis was conducted by using different definitions of multiclass 
psychotropic polypharmacy, including receipt of 3 or more psychotropic medications from 
different drug classes concurrently for ≥ 60 days and receipt of 4 or more psychotropic 
medications from different drug classes concurrently for ≥ 60 days. 
Analyses were conducted by using SAS 9.3 software (SAS Institute, Inc, Cary, NC) and 
STATA12 software (StataCorp, College Station, TX). 
RESULTS 
A total of 24,147 children and adolescents were diagnosed with a mental/behavioral 
disorder and had at least one pharmacy claim of psychotropic medication during the study 
period. The prevalence of multiclass psychotropic polypharmacy was 20.09%. Table M1.1 
shows the demographic and clinical characteristics of the children and adolescents on 
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psychotropic medications in both the single prescriber and multiple prescribers group along with 
the unadjusted results of differences between the non-polypharmacy and the polypharmacy 
patients. Majority of the patients in the study sample were male, 62.87% in the single prescriber 
group and 64.51% in the multiple prescriber group respectively. Substantial differences were 
observed between the multiple prescriber and single prescriber groups with respect to the 
diagnosis of attention-deficit hyperactivity disorder (81.69 vs. 68.45, p<0.001), bipolar 
disorder(s) (20.22% vs. 10.73%, p<0.001) and depression (17.89% vs 11.96%, p<0.001). Also, 
higher proportion of patients in the multiple prescriber group had a specialist involved in 
treatment as compared to the single prescriber group (55.42% vs. 40.74%, p<0.001).  
Single Prescriber involved in treatment: 
Non-polypharmacy patients were predominantly Hispanic (46.35%), while patients 
experiencing psychotropic polypharmacy were predominantly Caucasian (38.10%). The mean 
age of patients was higher in the polypharmacy group as compared to the non-polypharmacy 
group (10.15 ± 3.46 vs. 9.66 ± 4.07, p<0.001). Higher proportion of patients experiencing 
psychotropic polypharmacy were diagnosed with multiple mental/behavioral disorders compared 
to non-polypharmacy cases (60.34% vs. 38%, p<0.001). The average number of 
mental/behavioral disorders diagnosed in the polypharmacy group was higher than the non-
polypharmacy group (1.56 ± 0.99 vs. 2.10 ± 1.23, p<0.001). The most common diagnosis among 
both polypharmacy and non-polypharmacy groups was attention-deficit hyperactivity disorder, 
with polypharmacy group having a substantially higher proportion (84.42% vs. 66.42%, 
p<0.001). Diagnosis of bipolar disorder(s) was almost four times higher among the patients 
experiencing psychotropic polypharmacy as compared to non-polypharmacy patients (30.34% 
vs. 8.24%, p<0.001). On the other hand, a lower proportion of patients experiencing 
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psychotropic polypharmacy were diagnosed with learning disorder(s) compared to the non-
polypharmacy group (8.71% vs. 14.76%, p<0.001). A substantially higher proportion of patients 
experiencing psychotropic polypharmacy had a specialist involved in the treatment (79.73% vs. 
35.78%, p<0.001) as compared to those patients who were identified as non-polypharmacy.  
Multiple Prescribers involved in treatment: 
Similar to the single prescriber group, non-polypharmacy patients in the multiple 
prescriber group were predominantly Hispanic (40.02%), while patients experiencing 
psychotropic polypharmacy were predominantly Caucasian (45.70%). Patients in the 
polypharmacy group had a higher mean age as compared to the non-polypharmacy cases (10.08 
± 3.51 vs. 9.80 ± 3.63, p<0.001). Higher proportion of patients experiencing psychotropic 
polypharmacy were diagnosed with multiple mental/behavioral disorders compared to non-
polypharmacy cases (73.27% vs. 47.12%, p<0.001). The average number of mental/behavioral 
disorders diagnosed in the polypharmacy group was higher than the non-polypharmacy group 
(1.82 ± 1.15 vs. 2.72 ± 1.60, p<0.001). Patients receiving psychotropic polypharmacy had a 
relatively higher diagnosis of attention-deficit hyperactivity disorder as compared to non-
polypharmacy patients (84.12% vs. 80.62%, p<0.001). About four-times as many patients in the 
polypharmacy group were diagnosed with bipolar disorder(s) as compared to non-polypharmacy 
patients (40.17% vs. 11.49%, p<0.001). Higher proportion of patients who experienced 
psychotropic polypharmacy were diagnosed with depression (26.94% vs. 13.92%, p<0.001), 
anxiety disorder(s) (22.69% vs. 12.82%, p<0.001) and schizophrenia (11.21% vs. 3.48%, 
p<0.001) as compared to the non-polypharmacy patients. About twice as many patients 
experiencing psychotropic polypharmacy had a specialist involved in the treatment (80.12% vs. 
44.61%, p<0.001) as compared to those patients who were identified as non-polypharmacy. 
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About 18% of patients identified as receiving polypharmacy had more than 5 prescribers 
involved in the treatment, this number was much lower in the non-polypharmacy group (6.15%). 
Table M1.2 shows the average number of polypharmacy episodes per patient and the 
duration of polypharmacy episodes among patients receiving psychotropic polypharmacy. The 
duration of polypharmacy episodes was longer among patients with multiple prescribers 
involved in treatment. 
Multivariable Logistic Regression: 
Table M1.3 summarizes the results of the multivariable regression model. The most 
prominent factor associated with the receipt of psychotropic polypharmacy was the involvement 
of specialist in the treatment. Other factors positively associated with psychotropic 
polypharmacy were being a male, Caucasian race, diagnosis of ADHD and bipolar disorder(s) 
and involvement of multiple providers in treatment. The number of mental/behavioral disorder 
diagnosed was not a significant predictor in the single prescriber group but with was positively 
associated with polypharmacy in the multiple prescriber group. 
Single Prescriber involved in treatment:  
Patients with a specialist involved in the treatment had 5.3 times higher likelihood of 
receiving polypharmacy (OR=5.324; 95% CI 4.620-6.136). Males had a 14% higher likelihood 
of experiencing polypharmacy compared to females (OR=1.140; 95% CI 1.001-1.299). As 
compared to African Americans, Caucasians were 77% more likely to experience polypharmacy 
(OR=1.773; 95% CI 1.524-2.063) while Hispanics were 34% less likely to experience 
polypharmacy (OR=0.657; 95% CI 0.563-0.767). Patients diagnosed with ADHD and bipolar 
disorder(s) had 3.3 times (OR=3.328; 95% CI 2.595-4.269) and 3.2 times (OR=3.261; 95% CI 
2.567-4.142) higher likelihood of experiencing polypharmacy respectively, while patients 
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diagnosed with adjustment disorder(s) were 40% less likely to experience psychotropic 
polypharmacy (OR=0.602; 95% CI 0.454-0.798).  
Multiple Prescribers involved in treatment: 
The likelihood of receiving psychotropic polypharmacy was 3.6 times higher when a 
specialist was involved in treatment (OR=3.571; 95% CI 3.199-3.985). Males were 20% more 
likely to experience polypharmacy than females (OR=1.199; 95% CI 1.081-1.330). As compared 
to African Americans, Caucasians were 89% more likely to experience polypharmacy 
(OR=1.892; 95% CI 1.672-2.141) while Hispanics were 14% less likely to experience 
polypharmacy (OR=0.859; 95% CI 0.756-0.977). Each unit increase in the number of mental 
disorders diagnosed led to a 25% higher probability of experiencing polypharmacy (OR=1.252; 
95% CI 1.101-1.425). Diagnosis of ADHD and bipolar disorder(s) was highly associated with 
psychotropic polypharmacy with 1.8 times (OR=1.761; 95% CI 1.456-2.130) and 2.5 times 
(OR=2.509; 95% CI 2.091-3.010) higher likelihood among those diagnosed with the respective 
disorders. On the other hand patients diagnosed with adjustment disorder(s) were 28% less likely 
to experience psychotropic polypharmacy (OR=0.715; 95% CI 0.588-0.869). Unit increase in the 
number of prescribers involved in treatment was associated with 40% higher likelihood of 
receiving polypharmacy (OR=1.409; 95% CI 1.357-1.463).  
Post-hoc analysis:  
Tables M1.4 and M1.5 report the results for the post-hoc analysis for the difference in 
polypharmacy use among patients treated by PCPs vs those treated by specialists for both single 
prescriber and multiple prescriber involvement groups. 
Single Prescriber involved in treatment: 
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Predicted probability of receiving psychotropic polypharmacy was 0.0412 for patients 
that were prescribed medication by a PCP and 0.2205 for patients that were prescribed 
medication by specialists. The difference between the two groups was 0.1793 or 17.93 
percentage points. The decomposition estimated a coefficient of 0.0477 for the difference 
between patients visiting PCPs vs the specialists. This means that the observed characteristics 
explained 26.6% ([0.0477/0.1793]*100) of the difference between the two groups. Predisposing 
(Race) and need characteristics (diagnosis of bipolar, anxiety and depressive disorders) were the 
significant factors in the decomposition model. However, only some of the need characteristics 
viz. diagnosis of bipolar disorders (22.5%), anxiety (1.8%) and depression (3.1%) explained the 
difference in receipt of polypharmacy between the two groups, while the predisposing factor race 
had a negative coefficient.  
Multiple Prescribers involved in treatment: 
Predicted probability of receiving polypharmacy was 0.2713 for patients that were 
prescribed medication exclusively by PCPs and 0.4195 for patients that involved a specialist in 
prescription of medications. The difference between the two groups was 0.1482 or 14.82 
percentage points. The decomposition estimated a coefficient of 0.0359 for the difference 
between patients visiting PCPs only vs those with specialists involved in the treatment. This 
means that the observed characteristics explained 24.2% ([0.0359/0.1482]*100) of the difference 
between the two groups. Predisposing (patient-age, gender and race) and need characteristics 
(type of mental disorders diagnosed, number of mental disorders diagnosed and number of 
providers involved in treatment) were the significant factors in the decomposition model. 
However, only some of the need characteristics viz. diagnosis of bipolar disorders (42.6%) and 
depression (7.5%), and total number of mental disorders diagnosed (16.5%) substantially 
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explained the difference in receipt of polypharmacy between the two groups, while all the 
predisposing factors and some of the need characteristics had negative coefficients. Other minor 
factors explaining the difference in receipt of polypharmacy between the two groups were 
diagnosis of anxiety, learning disorders, ODD and schizophrenia. 
Sensitivity analysis: 
Risk factors associated with receipt of psychotropic polypharmacy defined using stricter 
definitions (3 or more psychotropic medications, and 4 or more psychotropic medications) were 
consistent with the observations of the main analysis. Involvement of specialist was still the 
single most prominent factor associated with psychotropic polypharmacy. Caucasian race, 
ADHD and bipolar diagnosis, and number of prescribers involved in the treatment were the 
positively associated risk factors while Hispanic race and diagnosis of learning and adjustment 
disorder were negatively associated risk factors for receipt of psychotropic polypharmacy.  
DISCUSSION 
 Prevalence of long-term psychotropic polypharmacy among the sample of a Texas 
Medicaid population diagnosed with mental/behavioral disorders was about 20%. This finding 
was consistent with the prevalence reported by Chen et al., in a study conducted among patients 
of similar age group, comparable study settings and using the same definition of long-term 
psychotropic polypharmacy.14 The pattern of psychotropic polypharmacy use suggests that 
multiple episodes of psychotropic polypharmacy occurred during the study period and continued 
for longer duration of about 200-230 days which was much higher than expected. Some patients 
even had episodes of polypharmacy that lasted throughout the two-year study period.  
 As expected and consistent with the literature24, receipt of psychotropic polypharmacy 
was strongly associated with patients’ race29, diagnosis and clinical complexity among both 
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single prescriber and multiple prescriber treatment groups. Our study identified that the 
involvement of a specialist (psychiatrist) in patient care was the most prominent factor associated 
with the receipt of psychotropic polypharmacy even after controlling for the patient 
demographics, diagnosis and observable measures for clinical complexity. Similar finding was 
only reported in one published study conducted among children and adolescents with Autism 
Spectrum Disorders. 23 In addition, we also observed that the likelihood of receiving 
psychotropic polypharmacy was even higher when specialist was the only prescriber involved in 
the treatment (single prescriber group), and when polypharmacy was defined as concurrent use 
of more than three or more than four psychotropic medications.  
          There are many potential reasons that could explain the differences in the practice of 
psychotropic polypharmacy between PCPs and specialists. It is known that specialists are more 
comfortable prescribing psychotropic medications as compared to primary care physicians30, as 
they have advanced training in the care and treatment of psychiatric disorders. As compared to 
PCPs, psychiatrists often emphasize more on symptom reduction rather than the disorder itself 
leading to prescription of more medications.31-33 Other than these factors, there is a general belief 
that the practice difference is mainly because psychiatrists see more severe and clinically 
complex patients than PCPs. 
        To advance the understanding of the contribution of predisposing and need factors in 
explaining the difference in the practice of psychotropic polypharmacy between PCPs and 
psychiatrists, we conducted a post-hoc analysis using the Fairlie decomposition method 
(extension of Blinder-Oaxaca [BO] decomposition). The post-hoc analyses showed that only 
about 25% of the difference in the prescription of psychotropic polypharmacy among PCPs and 
specialists (in both single and multiple provider groups) was explained by the need factors, 
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especially the diagnosis of bipolar disorders, depression and anxiety disorders. The number of 
mental disorders diagnosed was also a significant contributor to the difference in receipt of 
polypharmacy for the group with multiple prescribers involved in treatment. Predisposing factors 
like patient age, gender and race had negative coefficients and failed to explain the different 
prescribing behaviors between these provider specialties. The finding implies that various 
accesses to mental health specialist may be an important enabling factor that determines the use 
of long term psychotropic polypharmacy.  
         Long-term pediatric psychotropic polypharmacy is a concept that often bears negative 
implication, however, it is needed and well justified in certain occasions. In patients with bipolar 
disorders evidence-based studies have shown that polypharmacy is more effective than 
monotherapy.34 The use of atypical antipsychotic and a mood stabilizer for treatment of acute 
mania in bipolar patients has been approved by the FDA through two double-blind trials.35 The 
treatment guidelines for children and adolescents with bipolar disorders recommends the use of 
augmented therapy when monotherapy does not work.36 In adult patients with treatment-resistant 
depression the use of atypical antipsychotic and antidepressant has been approved by the FDA 
through a double-blind clinical trial.37 However, this combination might be used off-label by 
physicians in treatment of children and adolescents. In such cases, the benefits of these 
combinations should be weighed against the risk of adverse events such as weight gain and 
hyperlipidemia.  
       In our study we found that polypharmacy is a practice predominantly driven by the best-
trained group of providers: mental health specialists, and the observable need factors could only 
explain a quarter of the differences in practice. Even though some measures of clinical 
complexity, such as functional impairment, are not available in our data, the finding still 
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reiterates that psychotropic polypharmacy is a practice for which the significance and implication 
varies based on individual cases. It may not be appropriate to make a general judgment whether 
it is good or bad for patients. To ensure patient safety, the emphasis should be placed on 
promoting sufficient monitoring of potential drug-drug interaction, adverse drug events, and 
improving care coordination when multiple providers are involved in a care team.  
            There were some limitations to the study; the main limitation was that due to cross-
sectional nature of analysis only associations could be made between risk factors and 
polypharmacy. Secondly, like any other administrative claims based study, the findings of this 
study were based on the data of dispensed medications and do not confirm actual consumption 
by the patients. However, theoretically repeated fills of the medication are indicative of actual 
use. Furthermore, the information on patient’s medical history, patient preferences, disease 
severity and reason for medication prescription cannot be obtained from claims data, thus 
prohibiting the determination of their association with psychotropic polypharmacy.  
CONCLUSIONS 
The study highlights the extent of psychotropic polypharmacy use in the treatment of 
children and adolescents with mental/behavioral disorders. The most prominent factor associated 
with PP was involvement of a specialist in the treatment of mental/behavioral disorders. Only a 
quarter of the difference between PCPs and specialists with respect to prescription of PP was 
explained by observable need factors, underscoring the drastically different prescribing habits 
between PCPs and mental health specialists, and the complex implications of pediatric 
psychotropic polypharmacy. 
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Table M1. 1 Demographic and clinical characteristics 
Characteristic 
Single Prescriber involved in 
treatment  
(N=13,045; 54.02%) 
Multiple Prescribers involved in 
treatment 
 (N=11,102; 45.98%) 
Non-
polypharmacy  
 (N=11,575; 
88.73%)  
Psychotropic 
polypharmacy 
(N=1,470; 
11.27%) 
Non-
polypharmacy  
 (N=7,721; 
69.55%) 
Psychotropic 
polypharmacy 
(N=3,381; 
30.45%) 
Sex 
Male 7220 (62.38) 981 (66.73) 4976 (64.46) 2187 (64.69) 
Race 
African 
American 
2733 (23.61) 411 (27.96) 1836 (23.78) 709 (20.97) 
Alaskan 27 (0.23) 5 (0.34) 29 (0.38) 10 (0.30) 
Asian 175 (1.51) 7 (0.48) 101 (1.31) 31 (0.92) 
Caucasian 2908 (25.13) 560 (38.10) 2445 (31.67) 1545 (45.70) 
Hispanic 5364 (46.35) 452 (30.75) 3090 (40.02) 1013 (29.96) 
Not reported 367 (3.17) 35 (2.38) 220 (2.85) 73 (2.16) 
Age group 
0-3 691 (5.97) 8 (0.54) 196 (2.54) 36 (1.06) 
4-8 4197 (36.26) 548 (37.28) 2915 (37.75) 1216 (35.97) 
9-12 3455 (29.85) 500 (34.01) 2624 (33.99) 1165 (34.46) 
13-18 3232 (27.92) 414 (28.16) 1986 (25.72) 964 (28.51) 
Mean (± SD) 9.66 (4.07) 10.15 (3.46) 9.80 (3.63) 10.08 (3.51) 
Number of mental/behavioral disorders diagnosed 
0 562 (4.86) 12 (0.82) 132 (1.71) 16 (0.47) 
1 6615 (57.15) 571 (38.84) 3951 (51.17) 888 (26.26) 
2-4 4214 (36.41) 814 (55.37) 3371 (43.66) 1997 (59.07) 
≥5 184 (1.59) 73 (4.97) 267 (3.46) 480 (14.20) 
Mean (± SD) 1.56 (0.99) 2.10 (1.23) 1.82 (1.15) 2.72 (1.60) 
Type of  mental/behavioral disorder diagnosed 
ADHD 7688 (66.42) 1241 (84.42) 6225 (80.62) 2844 (84.12) 
Bipolar 
Disorder(s) 
954 (8.24) 446 (30.34) 887 (11.49) 1358 (40.17) 
Depression 1315 (11.36) 245 (16.67) 1075 (13.92) 911 (26.94) 
Anxiety 1308 (11.30) 217 (14.76) 990 (12.82) 767 (22.69) 
Learning 
Disorder(s) 
1708 (14.76) 128 (8.71) 954 (12.36) 329 (9.73) 
Adjustment 
Disorder(s) 
1112 (9.61) 134 (9.12) 822 (10.65) 516 (15.26) 
Conduct 
Disorder 
1144 (9.88) 202 (13.74) 881 (11.41) 4.70 (15.44) 
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Oppositional 
Defiant 
Disorder 
832 (7.19) 220 (14.97) 828 (10.72) 753 (22.27) 
Schizophrenia 297 (2.57) 63 (4.29) 269 (3.48) 379 (11.21) 
Number of prescribers involved in treatment 
2-4 NA NA 7246 (93.85) 2780 (82.22) 
≥5 NA NA 475 (6.15) 601 (17.78) 
Mean (± SD) NA NA 2.66 (1.05) 3.34 (1.55) 
Hospitalization/ ER-visit 
Yes 1103 (9.53) 202 (13.74) 1205 (15.61) 1045 (30.91) 
Specialist visited 
Yes 4142 (35.78) 1172 (79.73) 3444 (44.61) 2709 (80.12) 
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Table M1. 2 Summary of psychotropic polypharmacy use 
Parameter 
Psychotropic polypharmacy 
(N=4,851; 20.09%) 
Single Prescriber 
(N=1470; 30.30%) 
Multiple Prescribers 
(N=3381; 69.70%) 
Mean ± S.D. Median Range Mean ± S.D. Median Range 
Polypharmacy 
episodes per 
polypharmacy 
user 
1.43 ± 0.68 1 1-5 1.48 ± 0.72 1 1-5 
Duration of 
polypharmacy 
episodes (number 
of days) 
265.06 ± 192.80 201.5 60-730 283.63 ± 192.61 229.0 60-730 
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Table M1. 3 Multivariable Logistic Regression 
  
Characteristic 
  
Single Prescriber involved in 
treatment 
Multiple Prescribers involved in 
treatment 
OR 
  
95% CI P 
  
OR 
  
95% CI P 
  LL UL LL UL 
Age 
Age 1.002 0.984 1.020 0.827 0.974 0.959 0.989 <0.001 
Sex (Ref: Female) 
Male  1.140 1.001 1.299 0.049 1.199 1.081 1.330 <0.001 
Race (Ref: African American) 
Alaskan 2.064 0.677 6.288 0.203 1.154 0.498 2.671 0.739 
Asian 0.345 0.156 0.764 0.009 1.169 0.734 1.861 0.511 
Caucasian 1.773 1.524 2.063 <0.001 1.892 1.672 2.141 <0.001 
Hispanic 0.657 0.563 0.767 <0.001 0.859 0.756 0.977 0.020 
Not reported 1.238 0.834 1.839 0.290 1.194 0.872 1.633 0.269 
Number of mental/behavioral disorders diagnosed 
No. of MHD 1.046 0.87 1.257 0.633 1.252 1.101 1.425 <0.001 
Type of  mental/behavioral disorder diagnosed (Ref: No) 
ADHD 3.328 2.595 4.269 <0.001 1.761 1.456 2.130 <0.001 
Bipolar Disorder(s) 3.261 2.567 4.142 <0.001 2.509 2.091 3.010 <0.001 
Depression 1.437 1.101 1.876 0.008 1.158 0.949 1.412 0.149 
Anxiety 1.413 1.085 1.84 0.010 1.148 0.948 1.390 0.157 
Learning Disorder(s) 0.749 0.561 1.001 0.050 0.658 0.532 0.814 <0.001 
Adjustment 
Disorder(s) 
0.602 0.454 0.798 <0.001 0.715 0.588 0.869 <0.001 
Conduct Disorder 1.153 0.882 1.505 0.298 0.705 0.578 0.860 <0.001 
Oppositional Defiant 
Disorder 
1.141 0.879 1.481 0.323 1.007 0.836 1.214 0.941 
Schizophrenia 1.016 0.701 1.474 0.932 1.278 1.004 1.628 0.046 
Hospitalization/ER visit (Ref: No) 
Yes 1.139 0.938 1.382 0.189 1.016 0.891 1.158 0.815 
Number of prescribers involved in treatment 
No. of Prescribers NA NA NA NA 1.409 1.357 1.463 <0.001 
Specialist Visited (Ref: No) 
Yes 5.324 4.62 6.136 <0.001 3.571 3.199 3.985 <0.001 
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Table M1. 4 Nonlinear decomposition of psychotropic polypharmacy use between patients 
treated by PCPs and specialists 
 
Probability of receiving psychotropic polypharmacy for patients treated by 
PCPs 
0.0412 
Probability of receiving psychotropic polypharmacy for patients treated by 
specialists 
0.2205 
Difference in psychotropic polypharmacy use 0.1793 
Independent 
variables 
Decomposition Standard error P value % Contribution 
Predisposing Characteristics 
Age 0.0001 0.0009 0.882 0.06 
Male -0.0002 0.0003 0.436 0.11 
Race -0.0082 0.0013 0.000 -4.57 
Need Characteristics 
Number of 
mental/behavioral 
disorders 
diagnosed 
0.0048 0.0090 0.598 2.68 
ADHD 0.0011 0.0015 0.477 0.61 
Bipolar 
Disorder(s) 
0.0403 0.0044 0.000 22.48 
Depression 0.0055 0.0022 0.013 3.07 
Anxiety 0.0033 0.0015 0.028 1.84 
Learning 
Disorder(s) 
0.0003 0.0004 0.440 0.17 
Adjustment 
Disorder(s) 
-0.0030 0.0010 0.004 -1.67 
Conduct Disorder 0.0009 0.0009 0.327 0.50 
Oppositional 
Defiant Disorder 
0.0019 0.0021 0.375 1.06 
Schizophrenia -0.0001 0.0008 0.927 0.06 
Hospitalization/ER 
visit 
0.0011 0.0010 0.273 0.61 
Total explained by 
measurable 
characteristics 
0.0477   26.60 
 
 
 
 
 
 
 61 
  
Table M1. 5 Nonlinear decomposition of psychotropic polypharmacy use between patients 
treated by PCPs and specialists 
 
Probability of receiving psychotropic polypharmacy for patients treated by 
PCPs 
0.2713 
Probability of receiving psychotropic polypharmacy for patients treated by 
specialists 
0.4195 
Difference in psychotropic polypharmacy use 0.1482 
Independent 
variables 
Decomposition Standard error P value % Contribution 
Predisposing Characteristics 
Age -0.0052 0.0017 0.003 -3.51 
Male -0.0032 0.0008 0.000 -2.16 
Race -0.0184 0.0014 0.000 -12.42 
 
Number of 
mental/behavioral 
disorders 
diagnosed 
0.0244 0.0095 0.010 16.46 
ADHD -0.0170 0.0025 0.000 -11.47 
Bipolar 
Disorder(s) 
0.0631 0.0048 0.000 42.58 
Depression 0.0111 0.0035 0.002 7.49 
Anxiety 0.0060 0.0020 0.002 4.05 
Learning 
Disorder(s) 
0.0008 0.0004 0.025 0.54 
Adjustment 
Disorder(s) 
-0.0026 0.0011 0.014 -1.46 
Conduct Disorder -0.0016 0.0006 0.011 -1.08 
Oppositional 
Defiant Disorder 
0.0045 0.0017 0.006 3.04 
Schizophrenia 0.0048 0.0016 0.002 3.24 
Hospitalization/ER 
visit 
0.0011 0.0021 0.600 0.74 
Number of 
prescribers 
involved 
-0.0321 0.0016 0.000 -21.6 
Total explained by 
measurable 
characteristics 
0.0359   24.22 
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MANUSCRIPT 2  
Association between Physician Care Coordination and the Use of Psychotropic Polypharmacy in 
the Management of Pediatric Mental Disorders. 
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Abstract 
BACKGROUND:  Psychotropic polypharmacy has been a main safety concern in the 
management of pediatric mental disorders. Although seeing multiple providers has been 
identified as an important predictor for the receipt of polypharmacy, no study has yet assessed 
the impact of care coordination between providers.  
OBJECTIVE: To examine the association between the intensity of care coordination within a 
patient’s care team and the likelihood of the patient receiving psychotropic polypharmacy. 
METHODS: A retrospective cross-sectional study was conducted using the 2013-2015 
administrative claims data from a Medicaid Managed Care Organization (Texas Children’s 
Health Plan). The study included individuals: a) ≤18 years of age, b) diagnosed with a mental 
disorder, and c) received psychotropic prescriptions from multiple prescribers. Psychotropic 
polypharmacy (PP) was defined as the receipt of ≥ 2 psychotropic medications from different 
drug classes concurrently for 60 days or more.  Care coordination was measured using Care-
density (CD), a surrogate included in the AHRQ Care Coordination Measures Atlas, calculated 
as the ratio of the sum of patients shared by physician pairs within a patient’s care team to the 
total number of physician pairs. Guided by Andersen behavioral model, multivariate logistic 
regression analyses were conducted to assess the association between CD and patients’ 
likelihood of receiving PP after controlling for predisposing and need factors.  
RESULTS: A total of 24,147 children and adolescents who met the inclusion criteria were 
identified. Nearly half (n=11,102; 45.98%) of these individuals received PP prescribed by 
multiple providers. Logistic regression analysis showed a significant association between care 
density and the use of psychotropic polypharmacy. However, the direction of this relationship 
varied depending on the composition of the patient’s care team. Among patients with only PCPs 
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involved in their care team, patients in the higher CD group were 84% less likely to receive PP 
(OR=0.156; 95% CI 0.056-0.432) than those in low CD group. In contrast, among patients who 
had both PCPs and specialists involved in their care team, those in the higher CD group were 2.4 
times more likely to experience PP (OR=2.441; 95% CI 1.899-3.137). CD was not significantly 
associated with the receipt of PP in specialists only group.  
CONCLUSIONS: To the opposite from what has been perceived, higher care density between 
primary care providers and specialists resulted into increased use of psychotropic polypharmacy 
in children and adolescents.   
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INTRODUCTION 
 Despite the recommendations of clinical guidelines1 for the use of monotherapy in the 
treatment of children and adolescents with mental/behavioral disorders, the use of polypharmacy 
(concurrent use of medications) is quite common in psychiatric care with the overall prevalence 
ranging from 14% to as high as 73%.2-9 Psychotropic polypharmacy has heightened public health 
concern, because there is limited scientific evidence for understanding the immediate and/or 
long-term effects of its use on child’s growth and development. Additionally, psychotropic 
polypharmacy has been associated with a number of negative consequences including adverse 
events10,11, drug-drug interactions12,13, non-adherence14, higher-healthcare costs15, morbidity and 
mortality.16,17 
Due to the growing concerns, the State Medicaid Agencies in about 42 states in the 
United States have employed programs to monitor the prescribing of psychotropic medications in 
children.18 The Psychotropic Medication Utilization Review (PMUR) is one such set of 
parameters implemented by the State of Texas which monitors the psychotropic medication 
utilization in foster care children and has led to reduction in the inappropriate use of 
psychotropic medications in the Texas foster care population.19 However, the major limitation of 
these parameters is that it views inappropriate use of psychotropic medications as the outcome 
individual prescriber’s knowledge and attitude. The whole emphasis of these parameters is on the 
non-concordant behavior of a single individual physician providing care for the patient. It fails to 
acknowledge that some out-of-parameter uses, especially psychotropic polypharmacy, could 
arise from poor communication among providers rather than due to individual prescriber’s non-
concordant behavior. Previous studies have shown that involvement of multiple physicians in the 
provision of care is significantly associated with the receipt of polypharmacy.20, 21 Fragmented 
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care and lack of coordination among the physicians in the patient’s care team can lead to 
continuation of psychotropic polypharmacy in cases where it is not medically essential.22 
Care coordination involves deliberate organization of patient care activities such as 
accurate transfer of information, adequate communication, and appropriate follow-up care.23, 24 
Efficient channels of communication and collaboration among physicians are recognized 
catalysts to improved patient care.25 It allows input from multiple providers caring for the same 
patient, which produces decisions based on complete information, which in turn leads to better 
patient outcomes. Thus, in this study we want to examine whether better care coordination 
reduces the chances of receiving psychotropic polypharmacy.  
Recently, the concepts and techniques of social network analysis have been used to 
characterize the professional relationships among providers that result from day-to-day 
interactions, patient referrals and shared patients. Researchers have used the number of shared 
patients as an indicator of the strength of provider collaborative relationship. Pollack et al 
developed a measure called care-density, which determines the extent of patient sharing among 
physicians.26 It is hypothesized that providers who share greater number of patients have stronger 
collaborative relationships and will be able to provide better-coordinated care. A study by 
Barnett et al has validated that physicians who shared 8 or more patients had 80% probability of 
having an information-sharing relationship. 27 Several studies have demonstrated direct 
association between care-density and healthcare outcomes such as quality of care, cost of care 
and hospital outcomes. A study by Pollack et al, conducted using administrative databases from 
3 large commercial insurance plans showed that higher care-density was associated with lower 
odds of adverse events and 30-day readmissions in some of these settings.28  Another study by 
Pollack et al, showed that, among patients with congestive heart failure and diabetes, higher 
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care-density was associated with lower inpatient costs and reduced rates of hospitalization in the 
CHF cohort and lower outpatient costs but higher pharmacy costs in the diabetes cohort.26 A 
study by Ong et al examined the effect of care-density on multiple provider prescribing of 
benzodiazepines, it was found that provider pairs who shared greater number of patients were 
less likely to co-prescribe overlapping benzodiazepines.29 However, to our knowledge there has 
been no study that has looked at the relationship between care-density and psychotropic 
polypharmacy.  
Therefore, the objective of this study was to examine the relationship between care-
density and receipt of psychotropic polypharmacy among children and adolescents with 
mental/behavioral disorders. Further, we examined if this relationship varies depending on the 
specialty of physicians involved in the care team. 
METHODS 
Study Design and Data Source:  
A retrospective cross-sectional study was conducted using the administrative claims data 
from Texas Children’s Health Plan (TCHP) for the period of July 1, 2013 to June 30, 2015. Data 
was obtained for children and adolescents who were ever diagnosed with mental/behavioral 
disorders identified using ICD 9-CM codes (Appendix A) and who had continuous enrollment 
throughout the study period. TCHP is the nation’s first health maintenance organization (HMO) 
created just for children. It is an administrator for the State Children’s Health Insurance Program 
(CHIP) and STAR/Medicaid managed care programs through a contract with the state Medicaid 
administrator. TCHP has more than 400,000 members and over 1,100 primary care physicians, 
3,200 specialists and 60 hospitals that provide service and patient care to these members. TCHP 
data contains information on outpatient medical claims, and pharmacy claims. It also provides 
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information on the physician that was involved in the care/treatment during each patient visit 
(claim) such as the physician ID, gender, and specialty. Additionally, the data includes 
information on patient characteristics e.g. patient age, gender, and race. The data is de-identified 
in accordance with the Health Insurance Portability and Accountability Act (HIPAA) standards.  
Study Sample:  
The study included individuals who: a) were 0 to 18 years of age (children and 
adolescents), b) were diagnosed with a mental/behavioral disorder, c) had at least one pharmacy 
claim of psychotropic medication, and d) received prescription for psychotropic medication from 
multiple (at least two) prescribers during the study period. Further, these individuals were 
required to be continuously enrolled in the Texas Children Health Plan. Individuals who received 
prescription of psychotropic medication from a single prescriber throughout the study period 
were excluded from the study. The psychotropic medications considered in the study included: 
medications for attention-deficit hyperactivity disorder such as stimulants, non-stimulant 
(atomoxetine), alpha-agonists (guanfacine, clonidine), anti-depressant medications (selective 
serotonin norepinephrine reuptake inhibitors, serotonin reuptake inhibitors, and tricyclic 
antidepressants); antipsychotic agents (first and second generation); lithium; anticonvulsant 
mood-stabilizers (such as divalproex, oxcarbazepine, carbamazepine, lamotrigine), and 
anxiolytics (such as hydroxyzine and benzodiazepines).  
Outcome Measure: 
The outcome of interest was whether an individual had at least one episode of multiclass 
psychotropic polypharmacy during the study period, measured as a binary variable (1: Yes, 0: 
No). An episode of multiclass psychotropic polypharmacy was defined as the receipt of ≥ 2 
psychotropic medications from different drug classes concurrently for 60 days or more, with no 
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gaps in polypharmacy treatment. The 60-day overlap criterion is the most commonly 
implemented cutoff used to define polypharmacy, it avoids misclassifying instances of cross-
titration as polypharmacy. Patients who received psychotropic medications but did not have a 
polypharmacy episode at any time during the study period were classified as non-polypharmacy 
cases. Episodes of treatment were identified using the prescription fill date and the days’ supply 
information available from the pharmacy claims. Before measuring the episodes, overlapping 
days’ supply for the same medication were carried forward assuming that the patient finished the 
current prescription before starting on the refill prescription. Gaps in fills of the same medication 
of ≤ 15 days were allowed and adjusted in the calculation of the overlap. Further, the overlap 
was defined by drug class and not specific medications within class, so it was not necessary for a 
single medication within a class to overlap by ≥ 60 days with a particular medication in another 
class. Only unique combinations of drug classes of at least 60 days were considered.  
Exposure Measures: 
 The Andersen behavioral model was used to guide the selection of the potential 
predictors that could help explain the variation in the receipt of psychotropic polypharmacy 
among children with mental disorders. The components of the model including predisposing, 
enabling and need factors were defined based on literature and the relevance to the study’s 
objective. Predisposing factors included patient’s age, sex and race. Patient’s care team density 
was considered as the enabling factor. Need factors included number of mental/behavioral 
disorders diagnosed, type of mental/behavioral disorder diagnosed, and number of prescribers 
involved in treatment. 
Care-density was the primary independent variable of the study. To measure the care 
density, a physician patient-sharing network was first constructed using the pharmacy claims 
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data. A pair of physician was considered to have shared a patient if they both prescribed 
medications to a given patient anytime during the study period. A tie formed through such 
patient sharing was called a network tie. A set of all such possible ties between all the physicians 
in the data formed the physician patient-sharing network. Number of patients shared between 
physicians was used to characterize the collaborative relationships between the physicians. The 
extent of patient-sharing among the physicians was estimated using the “Care-Density” measure 
developed by Pollack et al. Care-Density is a patient-level measure, calculated as the ratio of the 
sum of patients shared by physician pairs within a patient’s care team to the total number of 
physician pairs within the patient’s care team.26 Figure M2.1 illustrates with example the 
calculation of Care-Density. Care-density corresponds to the care team’s cohesiveness, which is 
theoretically a representation of effective collaboration and communication between the patient’s 
care team. A greater Care-density value indicates stronger care team cohesiveness. Care-density 
was operationalized as a binary variable (0: CD <median and 1: CD ≥ median). 
Considering that patients with differing disease complexity might be treated by care 
teams consisting of various type of providers (e.g. PCPs only, or combination of PCPs and 
specialists, or even by multiple specialists), and that the need and the purpose of care 
coordination, and the actual information exchanged might differ between PCP-PCP, PCP-
specialist or specialist-specialist, stratification by physician specialty was necessary. To 
understand the variant implications of Care-Density on psychotropic polypharmacy in different 
types of patient’s care team, four patient groups were created based on the type of physicians 
involved in the care team: a) Primary Care Physicians (PCPs) only (e.g. general medicine, family 
medicine, and internal medicine), b) Specialists only (e.g. psychiatry, addiction medicine, 
psychosomatic medicine), c) PCPs and Specialists, and d) Others. 
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Statistical Analysis:  
Descriptive statistics, including frequencies, mean (± SD) and median were used to 
characterize patients’ demographics, clinical characteristics, and Care-Density. Separate Logistic 
regression models were fitted for patients with different types of care team to determine 
associations between Care-Density and the receipt of multiclass psychotropic polypharmacy after 
controlling for predisposing and need factors. 
 A-priori significance level of p<0.05 was chosen for the analyses. All analyses were 
conducted by using SAS 9.3 software (SAS Institute, Inc, Cary, NC).  
The study was reviewed and approved by the University of Houston Institutional Review 
Board. 
RESULTS  
A total of 24,147 children and adolescents were diagnosed with a mental/behavioral 
disorder and had at least one pharmacy claim of psychotropic medication during the study 
period. Nearly a half (n=11,102; 45.98%) of these psychotropic medication recipients received 
the prescriptions from multiple prescribers. According to the types of providers involved in 
prescribing, the 11,012 patients were divided into the following 4 groups: PCPs only (n=3,408; 
30.70%), specialists only (n= 1,921; 17.30%), PCP and specialists (n= 2,763; 24.89%); and other 
physician group (n=3,010; 27.11%). Table M2.1 presents the demographic and clinical 
characteristics of the patients in each of these groups. 
Patient characteristics: 
Patients in the 4 groups created based on types of care team varied in terms of age, race, 
type of mental disorders diagnosed, number of comorbid mental disorders, and the likelihood of 
having hospitalization/ER visits. Specifically, Caucasians were more likely to see PCPs, while 
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minorities especially Hispanics were more likely to see specialists.  More than 90% of patients 
with PCP only care team were diagnosed with ADHD, while in teams with specialist 
involvement, especially specialist only team there were significantly higher proportion of 
patients with depression, bipolar disorders, and schizophrenia.  
Receipt of psychotropic polypharmacy:  
The PCP + Specialist group was the group that had the highest utilization rate of 
psychotropic polypharmacy (42.89%), followed by specialist only group (40.50%), other 
physician group (33.55%), and with the lowest observed among the PCP only group (12%). The 
differences in demographic and clinical characteristics between the non-polypharmacy and the 
polypharmacy recipients by study groups are presented in Table M2.2.  
Predisposing factors:  
Across all study groups, majority of the patients in both psychotropic polypharmacy and 
non-polypharmacy group were male. Patients in the non-polypharmacy group were 
predominantly Hispanic, while patients in the psychotropic polypharmacy group were 
predominantly Caucasian. The average age of children in all the groups was about 10 years.  
Need Characteristics: 
       A substantially higher proportion of patients experiencing psychotropic polypharmacy were 
diagnosed with multiple mental/behavioral disorders compared to non-polypharmacy cases. 
Similarly, higher number of patients identified as receiving psychotropic polypharmacy had 
more than 5 prescribers involved in the treatment, as compared to the non-polypharmacy group. 
Higher proportion of patients experiencing polypharmacy were ever hospitalized or visited ER 
during the study period as compared to the non-polypharmacy cases.         
Enabling factors:  
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        Unlike the consistent differences observed on predisposing and need factors between 
polypharmacy recipient and non-recipients across the study groups, the implication of care 
density to receipt of psychotropic polypharmacy varies significantly across the study groups 
involving different types of prescribers.  
 The median care-density was higher among the non-polypharmacy recipients compared to the 
polypharmacy recipients among the PCP only and specialist only groups. In contrast, the median 
care-density was lower in the non-polypharmacy recipients compared to the polypharmacy 
recipients in the PCP + specialist and the other physician group. Higher care-density corresponds 
to stronger care team cohesiveness, suggesting that the care teams of the patients were more 
cohesive and integrated.  
Multivariable Logistic Regression: 
Table M2.3 presents the results for analysis conducted for each patient groups created on 
the basis of specialty of physicians involved in the patient care team. Median care density was 
used as the cutoff between high and low care density in all models.  
Enabling Characteristics: 
a) PCPs only: Among patients with only PCPs involved in the patient care team, patients in the 
high care-density group were 28% less likely to receive psychotropic polypharmacy (OR=0.722; 
95% CI 0.618-0.963).  
b) Specialists only:  Care density was not significantly associated with the receipt of 
psychotropic polypharmacy among patients who received psychotropic prescriptions from 
multiple specialists.  
c) PCPs and Specialists: Among patients who had both PCPs and specialists involved in their 
care team, those who received care from a provider team with higher care-density were 2 times 
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more likely to experience psychotropic polypharmacy (OR=2.006; 95% CI 1.680-2.397) than the 
ones whose care team had lower care-density.  
d) Others: In this group of patients, higher care-density was associated with 1.3 times higher 
probability of experiencing psychotropic polypharmacy (OR=1.295; 95% CI 1.07-1.563).  
Predisposing Characteristics: 
In all the groups Caucasians had a higher likelihood of receiving psychotropic 
polypharmacy than African Americans. The direction of the effect estimates for age, and gender 
were also consistent across the study groups. However, statistically significant differences were 
only detected among some provider groups.  Each year increase of age was associated with about 
4% decrease in the probability of receiving psychotropic polypharmacy among the PCP + 
specialist group (OR=0.966; 95% CI 0.938-0.994). Males had a 46% higher probability of 
receiving psychotropic polypharmacy than females in the PCP only group (OR=1.464; 95% CI 
1.135-1.889).  
Need Characteristics: 
 Increase in the number of prescribers involved in the treatment was associated with 
higher likelihood of receiving psychotropic polypharmacy among all the groups. Increase in the 
number of mental disorders diagnosed was associated with higher likelihood of receiving 
psychotropic polypharmacy in the PCP only and PCP + specialist groups. Diagnosis of learning 
disorder was associated with decreased probability of receiving psychotropic polypharmacy 
among the patients in PCP only, PCP + specialist and the other physician groups. Patients 
diagnosed with ADHD, bipolar disorder and depression had a higher probability of receiving 
psychotropic polypharmacy in the specialist only and other physician group than those not 
diagnosed with these disorders.  
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DISCUSSION 
This is the first study to examine the association between physician patient-sharing 
relationships and prescription of psychotropic polypharmacy, using the concepts of social 
network analysis. The primary finding of our study is that among the sample of Medicaid 
population enrolled in the Texas Children’s Health Plan, who were diagnosed and treated for 
mental/behavioral disorder(s), it was found that the enabling factor representing the extent of 
patient sharing between the patient’s care team (i.e. care-density) was strongly associated with 
the likelihood of receiving psychotropic polypharmacy. However, the relationship between care-
density and psychotropic polypharmacy varied depending on the specialty of physicians involved 
in the care team. It was observed that, among the patients with only primary care physicians 
involved in the care team, higher care-density was associated with lower likelihood of receiving 
psychotropic polypharmacy. Similar finding was observed in the patients whose care team 
composed of physicians other than PCPs and/or specialists. On the other hand, in the group of 
patients who either only had specialists in the care team or had both PCPs and specialists, higher 
care-density was associated with higher likelihood of receiving psychotropic polypharmacy.  
The various implications of care density in patient groups seen by different care teams 
could be because the study groups represent patients of differing diagnosis, clinical complexity, 
and therefore of differing needs for psychotropic polypharmacy. When the care team consists of 
PCPs only, nearly 90% of patients had a single ADHD diagnosis. The clinical practice guidelines 
for diagnosis and treatment of ADHD recommends the use of either behavioral therapy, 
medication or a combination of behavioral therapy and medication for the treatment of 
uncomplicated ADHD depending on the age of the child.30 Combination or augmentation 
therapy is not recommended for management of ADHD unless the patient is diagnosed with 
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comorbid conditions like bipolar disorders, tics or anxiety disorders in which case short-term 
polypharmacy might be used.31 Moreover, seeing multiple PCPs does not suggest increased 
clinical complexity in our study. It rather implies that the patients either changed his/her primary 
care provider or receipt of prescriptions from multiple PCPs from a shared practice as TCHP is a 
HMO that requires the patient to select a primary care provider as the primary contact of most 
medical concerns. The patient group who were seen by multiple mental health specialists are 
distinctively different from the group that had only PCPs in their care team. Children and 
adolescents in this group had much higher prevalence of mood disorders, especially bipolar 
disorder and depression as compared to patients who have seen PCPs only. Use of psychotropic 
polypharmacy in treatment of bipolar disorders is quite common in clinical practice. Evidence-
based studies have shown that polypharmacy is more effective than monotherapy in some bipolar 
disorder patients. Combination treatment with atypical antipsychotic and a mood stabilizer for 
acute mania has been approved by FDA through two double-blind trials.32 The treatment 
guidelines for children and adolescents with bipolar disorders recommends the use of augmented 
therapy when monotherapy does not work.33 The combination of atypical antipsychotic and 
antidepressant has been approved by FDA based on a double-blind clinical trial34 for adult 
patients with treatment-resistant depression. However, this combination might be used off-label 
by physicians in treatment of children and adolescents with treatment-resistant depression. 
Moreover, this group is also the most severe subgroup with respect to clinical complexity. About 
32% percent of children and adolescents in this sub-cohort had either been hospitalized or had an 
ER-visit and about 75% had multiple comorbid psychiatric disorders.  Therefore, children and 
adolescents in this group are in great need of intensive pharmacotherapy including psychotropic 
polypharmacy. The patients who have received psychotropic prescriptions from both PCPs and 
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specialists had diagnostic profile and clinical complexity more similar to patients who received 
care from multiple providers than those received care from PCPs only. These patients often are 
identified by their PCPs or self-identified as needing specialty care which implies that treatment 
escalation or adjustment is expected. The last group represents patients who were prescribed 
psychotropic medications by non-specialist, non-PCP physicians. Some of these patients were 
also prescribed medications by PCPs and specialists but the majority of the care is provided by 
non-PCP, non-specialist physicians. These type of physicians usually provide prescriptions for 
maintenance therapy and are conservative in their approach like PCPs. Care-coordination 
strategies in these group might be focused more towards adequacy of treatment and maintenance 
therapy, thus the observed negative relationship with polypharmacy. 
Care density is a surrogate measure for care communication and collaboration. It is based 
on the concept and methods of social network analysis and patient-sharing. Networks built on the 
basis of patient-sharing relationships have been previously validated by Barnett et al.27 Care-
density as a measure of collaboration and coordination has been used to study healthcare 
outcomes related to quality of care, cost of care and hospital admissions.26, 28 Care coordination is 
defined as “the deliberate organization of patient care activities between two or more participants 
involved in a patient’s care to facilitate the appropriate delivery of health care services”35 The 
purpose of collaboration is to better meet the need of patients, provide sufficient treatment, and 
reduce redundancy and medication errors. Probably due to the various needs of each patient 
subgroup on psychotropic polypharmacy, the care collaboration therefore had different 
implications.  Specifically, higher care density or better care coordination leads to less use of 
psychotropic polypharmacy in patients with uncomplicated ADHD (those who see PCPs only), 
but increased use among the more severe cases with bipolar disorders or multiple comorbid 
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mental disorders who are seeking for specialty care (those who see both PCP and psychiatrists).   
For those clinically complex patient group who have seen multiple psychiatrists, polypharmacy 
might be justified or might even be a norm, thus, probably care-coordination does not play a 
major role in prescription of polypharmacy.  
Our study suggests that the receipt of psychotropic polypharmacy, is not only determined 
by predisposing and need factors as reported in the previous literature36, 37, but also strongly 
associated with enabling factor such as care collaboration within a patient’s care team. For 
patients who have ever seen by a specialist, higher care density is either associated with 
increased use of psychotropic polypharmacy (PCP+ specialists, other specialists), or had no 
impact on its utilization (multiple specialists).  The findings suggest that, to the opposite from the 
stigma associated with pediatric psychotropic polypharmacy, the practice is mainly resulting 
from a patient’s clinical complexity and improved collaboration within the patient’s care team. 
Psychotropic polypharmacy might be needed in these patients and the utilization could be well 
justified. Appropriate follow-up and monitoring of these patients is all the more important to 
make sure that psychotropic polypharmacy is effective in reducing symptoms and not leading to 
unwanted side effects. Number of prescribers involved was a strong predictor of psychotropic 
polypharmacy, thus it can be said that care-density alone is not adequate representation of care 
coordination, other aspects of coordination should also be explored. Further research is needed to 
understand the drug-drug interaction, sufficiency of monitoring. 
 Recently, the “Care Coordination Measures Atlas Update” developed for the Agency for 
Healthcare Research and Quality (AHRQ) elaborated on Social Network Analysis as an 
emerging method for the measurement of care coordination.37 Patient sharing networks 
developed using the concepts of Social Network Analysis represent a probable mechanism of 
 79 
  
care coordination. Early work by Barnett et al27, Pollack et al26, 28, Ong et al29 and others is 
promising and has shown that care density is independently associated with various aspects of 
health care such as quality of care, prescribing error rates and costs. Our study adds to this pool 
of research and advances the understanding of using patient sharing networks to measure care 
coordination in mental health care.  
 There were several limitations to this study. First, this was a cross-sectional study thus 
the longitudinal continuity of care could not be measured. Only associations between patient-
sharing and psychotropic polypharmacy were determined. Second, the structural features of the 
relationships between physicians such as practice size, type of practice and geographical 
variations could not be adjusted for during the development of patient-sharing networks. Third, 
care-density was calculated as a claim based measure of coordination on the assumption that 
physicians who share more patients are more likely to collaborate, however whether care was 
actually coordinated for a given patient could not be estimated using the current data. Lastly, 
clinical severity of the patient could not be assessed using the claims data. Third, even though 
physicians share high number of patients it is possible that these physicians do not necessarily 
exchange information on particular patient’s care plan, rather communicate about their practice 
in general. Lastly, care-density might be affected by the structure of health care organizations 
(size of practice, mode of information exchange, and type of practice), which could not be 
accounted for in this study.   
CONCLUSIONS 
 This study found significant associations between care-density and psychotropic 
polypharmacy. It was further observed that this relationship varied depending on the composition 
of the patient’s care team. Care-density as a measure of care coordination is still in its developing 
 80 
  
stages, however it might be possible to use care-density in combination with other measures of 
care coordination to completely characterize multiple aspects of coordination. It can act as a 
supplement to the existing parameters implemented by State Medicaid agencies to identify 
patients at higher risk of psychotropic polypharmacy and to employ interventions for improving 
care coordination.  
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Table M2. 1 Demographic and clinical characteristics by study groups. 
Characteristic 
Multiple prescribers involved in treatment (N=11,102; 100%) 
PCPs only 
(N=3,408) 
Specialists only 
(N=1,921) 
PCP + 
Specialist 
(N=2,763) 
Others 
(N=3,010) 
PREDISPOSING CHARACTERISTICS 
Sex 
Male 2367 (69.45) 1135 (59.11) 1804 (65.29) 1857 (61.69) 
Race 
African 
American 
689 (20.22) 477 (24.83) 645 (23.34) 734 (24.39) 
Caucasian 1371 (40.23) 499 (25.98) 1036 (37.50) 1084 (36.01) 
Hispanic 1200 (35.21) 870 (45.29) 996 (36.50) 1037 (34.45) 
Others 148 (4.34) 75 (3.90) 86 (3.11) 155 (5.15) 
Age group 
0-3 46 (1.35) 15 (0.78) 21 (0.76) 150 (4.98) 
4-8 1348 (39.55) 596 (31.03) 1077 (38.98) 1110 (36.88) 
9-12 1362 (39.96) 593 (30.87) 923 (33.41) 911 (30.27) 
13-18 652 (19.13) 717 (37.32) 742 (26.85) 839 (27.87) 
Mean (± SD)* 9.56 ± 3.20 10.73 ± 3.63 9.92 ± 3.50 9.67 ± 3.98  
ENABLING CHARACTERISTICS 
Care-Density 
Mean (± SD) 24.89 ± 31.12 38.16 ± 70.37 34.18 ± 55.94 29.89 ± 44.05 
Median 
(Range) 
13.00 8.33 5.67 8.33 
NEED CHARACTERISTICS 
Number of mental/behavioral disorders diagnosed 
0 52 (1.53) 1 (0.05) 17 (0.62) 78 (2.59) 
1 2174 (63.79) 485 (25.25) 882 (31.92) 1298 (43.12) 
2-4 1131 (33.19) 1199 (62.42) 1607 (58.16) 1431 (47.54) 
≥5 51 (1.50) 236 (12.29) 257 (9.30) 203 (6.74) 
Mean (± SD) 1.53 ± 0.92 2.68 ± 1.49 2.41 ± 1.45 2.06 ± 1.38 
Type of mental/behavioral disorder diagnosed 
ADHD 3,121 (91.58) 1431 (74.49) 2329 (84.29) 2188 (72.69) 
Bipolar 
Disorder(s) 
111 (3.26) 798 (41.54) 776 (28.09) 560 (18.60) 
Depression 200 (5.87) 608 (31.65) 629 (22.77) 549 (18.24) 
Anxiety 248 (7.28) 430 (22.38) 529 (19.15) 550 (18.27) 
Learning 
Disorder(s) 
357 (10.48) 197 (10.26) 302 (10.93) 427 (14.19) 
Adjustment 
Disorder(s) 
255 (7.48) 330 (17.18) 399 (14.44) 354 (11.76) 
Conduct 
Disorder 
328 (9.62) 300 (15.62)  440 (15.92) 335 (11.13) 
 86 
  
Oppositional 
Defiant 
Disorder 
195 (5.72) 417 (21.71) 591 (21.39) 378 (12.56) 
Schizophrenia 52 (1.53) 213 (11.09) 198 (7.17) 185 (6.15) 
Number of prescribers involved in treatment 
2-4 3217 (94.40) 1858 (96.72) 2457 (88.93) 2494 (82.86) 
≥5 191 (5.60) 63 (3.28) 306 (11.07) 516 (17.14) 
Mean (± SD) 2.62 ± 1.08 2.45 ± 0.83 3.01 ± 1.22 3.28 ± 1.55 
Hospitalization/ ER-visit 
Yes 282 (8.27) 613 (31.91) 640 (23.16) 715 (23.75) 
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Table M2. 2 Demographic and clinical characteristics of patients stratified by receipt of polypharmacy.  
Characterist
ic 
Multiple prescribers involved in treatment (N=11,102; 100%) 
PCPs only Specialists only PCP + Specialist Others 
Non-
polypharma
cy 
(N=3,000; 
88.03%) 
Psychotropi
c 
polypharma
cy (N=408; 
11.97%) 
Non-
polypharma
cy 
(N=1,143; 
59.50%) 
Psychotropi
c 
polypharma
cy (N=778; 
40.50%) 
Non-
polypharma
cy 
(N=1,578; 
57.11%) 
Psychotropi
c 
polypharma
cy 
(N=1,185; 
42.89%) 
Non-
polypharma
cy 
(N=2,000; 
66.45%) 
Psychotropi
c 
polypharma
cy 
(N=1,010; 
33.55%) 
PREDISPOSING CHARACTERISTICS 
Sex 
Male 
2,064 
(68.80) 
303 (74.26) 670 (58.67) 465 (59.77) 
1,023 
(64.83) 
781 (65.91) 
1219 
(60.95) 
638 (63.17) 
Race 
African 
American 
621 (20.70) 68 (16.67) 286 (25.02) 191 (24.55) 406 (25.73) 239 (20.17) 523 (26.15) 211 (20.89) 
Caucasian 
1144 
(38.13) 
227 (55.64) 239 (20.91) 260 (33.42) 452 (28.64) 584 (49.28) 610 (30.50) 474 (46.93) 
Hispanic 
1095 
(36.50) 
105 (25.74) 573 (50.13) 297 (38.17) 672 (42.59) 324 (27.34) 750 (37.50) 287 (28.42) 
Not reported 140 (4.67) 8 (1.96) 45 (3.94) 30 (3.86) 48 (3.04) 38 (3.21) 117 (5.85) 38 (3.76) 
Age group 
0-3 43 (1.43) 3 (0.74) 8 (0.70) 7 (0.90) 10 (0.63) 11 (0.93) 135 (6.75) 15 (1.49) 
4-8 
1172 
(39.07) 
176 (43.14) 380 (33.25) 216 (27.76) 625 (39.61) 452 (38.14) 738 (36.90) 372 (36.83) 
9-12 
1182 
(39.40) 
180 (44.12) 344 (30.10) 249 (32.01) 516 (32.70) 407 (34.35) 582 (29.10) 329 (32.57) 
13-18 603 (20.10) 49 (12.01) 411 (35.96) 306 (39.33) 427 (27.06) 315 (26.58) 545 (27.25) 294 (29.11) 
Mean (± 
SD)* 
9.62 ± 3.25 9.14 ± 2.78 10.61 ± 3.66 10.92 ± 3.59 9.96 ± 3.55 9.88 ± 3.43 9.49 ± 4.12 10.05 ± 3.66 
ENABLING CHARACTERISTICS 
Care-Density 
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Mean (± SD) 
25.40 ± 
31.90 
21.15 ± 
24.32 
43.90 ± 
79.66 
29.72 ± 
52.83 
26.48 ± 
51.86 
44.43 ± 
59.44 
31.16 ± 
48.24 
27.37 ± 
34.15 
Median 14.00  11.00 9.00 7.42 3.58 11.50 6.33 12.74  
NEED CHARACTERISTICS 
Number of mental/behavioral disorders diagnosed 
0 47 (1.57) 5 (1.23) 1 (0.09) 0 (0) 14 (0.89) 3 (0.25) 70 (3.50) 8 (0.79) 
1 
2002 
(66.73) 
172 (42.16) 367 (32.11) 118 (15.17) 576 (36.50) 306 (25.82) 
1006 
(50.30) 
292 (28.91) 
2-4 922 (30.73) 209 (51.23) 686 (60.02) 513 (65.94) 897 (56.84) 710 (59.92) 866 (43.30) 565 (55.94) 
≥5 29 (0.97) 22 (5.39) 89 (7.79) 147 (18.89) 91 (5.77) 166 (14.01) 58 (2.90) 145 (14.36) 
Mean (± SD) 1.46 ± 0.84 2.06 ± 1.25 2.37 ± 1.33 3.14 ± 1.59 2.18 ± 1.27 2.71  ± 1.60 1.75 ± 1.12 2.66  ± 1.63 
Type of mental/behavioral disorder diagnosed 
ADHD 
2731 
(91.03) 
390 (95.59) 843 (73.75) 588 (75.58) 
1298 
(82.26) 
1031 
(87.00) 
1,353 
(67.65) 
835 (82.67) 
Bipolar 
Disorder(s) 
79 (2.63) 32 (7.84) 325 (28.43) 473 (60.80) 295 (18.69) 481 (40.59) 188 (9.40) 372 (36.83) 
Depression 156 (5.20) 44 (10.78) 317 (27.73) 291 (37.40) 330 (20.91) 299 (25.23) 272 (13.60) 277 (27.43) 
Anxiety 185 (6.17) 63 (15.44) 214 (18.72) 216 (27.76) 276 (17.49) 253 (21.35) 315 (15.75) 235 (23.27) 
Learning 
Disorder(s) 
308 (10.27) 49 (12.01) 126 (11.02) 71 (9.13) 190 (12.04) 112 (9.45) 330 (16.50) 97 (9.60) 
Adjustment 
Disorder(s) 
218 (7.27) 37 (9.07) 186 (16.27) 144 (18.51) 207 (13.12) 192 (16.20) 211 (10.55) 143 (14.16) 
Conduct 
Disorder 
275 (9.17) 53 (12.99) 166 (14.52) 134 (17.22) 250 (15.84) 190 (16.03) 190 (9.50) 145 (14.36) 
Oppositional 
Defiant 
Disorder 
120 (4.00) 75 (18.38) 219 (19.16) 198 (25.45) 296 (18.76) 295 (24.89) 193 (9.65) 185 (18.32) 
Schizophreni
a 
35 (1.17) 17 (4.17) 86 (7.52) 127 (16.32) 81 (5.13) 117 (9.87) 67 (3.35) 118 (11.68) 
Number of prescribers involved in treatment 
2-4 
2841 
(94.70) 
376 (92.16) 
1126 
(98.51) 
732 (94.09) 
1,479 
(93.73) 
978 (82.53) 
1800 
(90.00) 
694 (68.71) 
≥5 159 (5.30) 32 (7.84) 17 (1.49) 46 (5.91) 99 (6.27) 207 (17.47) 200 (10.00) 316 (31.29) 
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Mean (± SD) 2.59 ± 1.03 2.84 ± 1.38 2.29 ± 0.63 2.67 ± 1.03 2.73 ± 1.02 3.40 ± 1.34 2.92 ± 1.22 3.98 ± 1.87 
Hospitalization/ ER-visit 
Yes 238 (7.93) 44 (10.78) 297 (25.98) 316 (40.62) 290 (18.38) 350 (29.54) 380 (19.00) 335 (33.17) 
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Table M2. 3 Multivariate logistic regression model by study groups. 
Characteristic 
PCPs only Specialists only PCP + Specialist Others 
OR 
95% 
CI 
P OR 
95% 
CI 
P OR 
95% 
CI 
P OR 
95% 
CI 
P 
ENABLING CHARACTERISTICS 
Care-Density (Ref: less than 100) 
Care-Density  
(Higher than 
median) 
0.722 
0.618-
0.963 
0.022 0.930 
0.752-
1.149 
0.499 2.006 
1.680-
2.397 
<0.00
1 
1.295 
1.073-
1.563 
0.007 
PREDISPOSING CHARACTERISTICS 
Age 
Age 0.963 
0.928-
1.000 
0.050 1.005 
0.971-
1.041 
0.780 0.966 
0.938-
0.994 
0.018 0.993 
0.966-
1.020 
0.605 
Sex (Ref: Female) 
Male 1.464 
1.135-
1.889 
0.003 1.169 
0.935-
1.463 
0.171 1.174 
0.975-
1.415 
0.091 1.131 
0.933-
1.371 
0.210 
Race (Ref: African American) 
Caucasian 1.817 
1.339-
2.464 
<0.00
1 
1.479 
1.114-
1.964 
0.007 2.190 
1.754-
2.733 
<0.00
1 
1.751 
1.397-
2.194 
<0.00
1 
Hispanic 0.926 
0.661-
1.298 
0.656 0.798 
0.617-
1.033 
0.087 0.889 
0.706-
1.119 
0.317 1.049 
0.823-
1.337 
0.701 
Not reported 0.567 
0.259-
1.241 
0.156 1.017 
0.591-
1.752 
0.951 1.600 
0.979-
2.615 
0.061 1.368 
0.873-
2.142 
0.171 
NEED CHARACTERISTICS 
Number of mental/behavioral disorders diagnosed 
No. of MHD 1.884 
1.383-
2.565 
<0.00
1 
0.911 
0.699-
1.186 
0.488 1.346 
1.053-
1.719 
0.018 1.232 
0.975-
1.557 
0.081 
Type of mental/behavioral disorder diagnosed (Ref: No) 
ADHD 1.781 
0.954-
3.326 
0.070 2.487 
1.673-
3.695 
<0.00
1 
1.334 
0.929-
1.918 
0.119 2.421 
1.736-
3.377 
<0.00
1 
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Bipolar Disorder(s) 1.508 
0.847-
2.684 
0.163 4.360 
3.036-
6.261 
<0.00
1 
2.117 
1.522-
2.945 
<0.00
1 
3.489 
2.483-
4.902 
<0.00
1 
Depression 1.059 
0.612-
1.832 
0.838 1.588 
1.068-
2.361 
0.022 0.891 
0.620-
1.278 
0.529 1.594 
1.102-
2.306 
0.013 
Anxiety 1.431 
0.877-
2.334 
0.151 1.632 
1.110-
2.401 
0.013 1.001 
0.709-
1.414 
0.994 1.066 
0.749-
1.518 
0.723 
Learning Disorder(s) 0.423 
0.256-
0.700 
<0.00
1 
1.165 
0.743-
1.828 
0.505 0.513 
0.349-
0.753 
<0.00
1 
0.558 
0.375-
0.831 
0.004 
Adjustment 
Disorder(s) 
0.394 
0.230-
0.677 
<0.00
1 
1.039 
0.715-
1.508 
0.842 0.677 
0.474-
0.968 
0.032 0.759 
0.521-
1.104 
0.149 
Conduct Disorder 0.547 
0.336-
0.890 
0.015 0.945 
0.626-
1.428 
0.789 0.597 
0.420-
0.849 
0.004 0.831 
0.567-
1.219 
0.345 
Oppositional Defiant 
Disorder 
2.127 
1.329-
3.403 
0.002 1.200 
0.825-
1.746 
0.341 0.814 
0.584-
1.136 
0.227 1.002 
0.703 
1.428 
0.992 
Schizophrenia 1.776 
0.856-
3.684 
0.123 1.657 
1.071-
2.563 
0.023 0.995 
0.636-
1.557 
0.982 1.682 
1.053-
2.687 
0.030 
Hospitalization/ER visit (Ref: No) 
Yes 1.084 
0.743-
1.581 
0.677 0.946 
0.713-
1.255 
0.702 1.124 
0.894-
1.414 
0.316 1.054 
0.831-
1.337 
0.664 
Number of prescribers involved in treatment 
No. of Prescribers 1.120 
1.024-
1.226 
0.014 1.676 
1.461-
1.922 
<0.00
1 
1.395 
1.290-
1.509 
<0.00
1 
1.447 
1.360-
1.540 
<0.00
1 
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Figure M2. 1 PCN for understanding Care Density 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An example of care density is illustrated in Figure M2.1. In this figure, there are four providers 
represented by circles (labeled A through D) and 4 patients represented by different line styles 
(solid, dotted, long dashed, and short dashed).  Care density equals the sum of the number of 
shared patients among a patient’s providers divided by the total number of provider pairs that a 
patient sees.  For example, the patient represented by the dotted line sees providers C and D.  
The numerator of care density is the 3 patients shared by these doctors.  The denominator is 1 for 
1 pair of doctors.  Thus, the patient represented by the solid line has a care density of 3 divided 
by 1 or 3.  The patient represented by the long dashed line sees providers B, C, and D.  Provider 
pair B and D share 0 patients, pair B and C share 1, and pair C and D share 3.  The numerator is 
4.  The denominator is 3 pairs of doctors.  Care density for the patient represented by the long 
dashed line is 4 divided by 3 or 1.33. 
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MANUSCRIPT 3  
Physician Peer-influence on Prescribing Psychotropic Polypharmacy in the Treatment of 
Children and Adolescents with Mental Disorders  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
Abstract 
BACKGROUND:  Prescription of psychotropic polypharmacy in the management of pediatric 
mental disorders is on the rise. Studies have shown that, physicians’ prescribing behaviors can be 
influenced by their peers, however no study has yet examined the relationship between physician 
peer-influence and prescription of psychotropic polypharmacy.  
OBJECTIVE: To examine the effect of physician peer-influence on the prescription of 
psychotropic polypharmacy among children and adolescents treated for mental/behavioral 
disorders. 
METHODS: A retrospective cross-sectional study was conducted using the 2013-2015 
administrative claims data from Texas Children’s Health Plan (TCHP). The study included 
individuals: a) ≤18 years of age, b) diagnosed with a mental disorder, and c) received 
psychotropic prescriptions from a single prescriber during the study period. The outcome of 
interest was psychotropic polypharmacy, defined as the receipt of ≥ 2 psychotropic medications 
from different drug classes concurrently for 60 days or more. Multilevel generalized linear mixed 
models (GLIMMIX) was used to study the association between prescriber-level social network 
influence measures (created using patient-sharing relationships between physicians) and patient-
level risks of receiving psychotropic polypharmacy by adjusting for the practice-level (practice 
size, type of practice), physician-level (peer-influence measures, gender and specialty) and 
patient-level (patient age, gender, race; number of mental/behavioral disorders diagnosed; type 
of mental/behavioral disorder diagnosed; and whether a specialist was involved in treatment) 
covariates.  
RESULTS: A total of 24,147 children and adolescents were diagnosed with a mental disorder 
and had received at least one psychotropic medication. Of these, nearly half (n=13,045; 54.02%) 
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met the study inclusion criteria. The multilevel models found that as a physician is exposed more 
to their peers prescribing polypharmacy through sharing of same patients, there is 77% higher 
likelihood of receiving psychotropic polypharmacy (OR=1.766; 95% CI 1.027-3.037); similarly, 
as physicians occupy more similar position in patient-sharing network, there is almost 4-times 
higher likelihood of receiving psychotropic polypharmacy (OR=4.236; 95% CI 2.071-8.666). 
Other than these physician-level peer influence measures, physician specialty and patient-level 
factors including gender, race and diagnosis of attention-deficit/hyperactivity disorder, bipolar 
disorder and depression were associated with prescription of psychotropic polypharmacy. 
CONCLUSIONS: Physician peer-influence was strongly associated with the prescription of 
psychotropic polypharmacy. Our study implies that targeting and changing the prescribing 
behaviors of guideline non-concordant physicians would be useful to enhance the diffusion of 
guideline concordant practices among other physicians. 
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INTRODUCTION 
 The use of psychotropic polypharmacy (combination of psychotropic medications) to 
treat mental/behavioral disorders is on the rise among children and adolescents despite the 
recommendations of the clinical guidelines1 to use monotherapy in this population. The overall 
prevalence of psychotropic polypharmacy in the US pediatric population ranges from 14% to 
73% 2-9, which is alarming given the number of health concerns associated with it, such as 
adverse events10,11, drug-drug interactions12,13, non-adherence14, higher-healthcare costs15, 
morbidity and mortality16,17. There is only limited scientific evidence for understanding the 
immediate or long-term effects of polypharmacy on the child’s growth and development, making 
it an important public health concern.18 
 Due to the growing concerns, many of the State Medicaid agencies throughout the US 
have introduced programs to monitor the prescribing of psychotropic medications in children and 
adolescents.19 One such program that has led to a significant reduction in the instances of 
psychotropic polypharmacy in the foster care population in the state of Texas is the Psychotropic 
Medication Utilization Review (PMUR) program.20 The existing PMUR process views guideline 
non-concordant prescribing (especially polypharmacy) as the outcome of individual physicians’ 
knowledge and attitude. The whole emphasis of these programs is on the non-concordant 
behavior of a single individual physician. However, these programs fail to consider the effect of 
the environment from which such behavior might have originated. Specifically, the effect of 
physician peer-influence on the prescribing practices is not accounted by these programs. During 
the provision of care, physicians interact with multiple other physicians either within the 
organization or outside of it, forming social and professional relationships with their peers. 
Physicians seldom work as isolated individuals, they are a part of a social structure where they 
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exert influence on each other as a result of day-to-day interactions, referrals and sharing of 
patients.21 Most of the times peer-influence shapes the practice behaviors of the physicians. 
Clusters of physicians usually adopt the behavior of their peers and opinion leaders (most 
influential physicians) during the provision of care. Previous studies have shown that, 
physicians’ prescribing behavior can be influenced by their peers in addition to their own 
personal preferences.22, 23, 24 
In the context of psychiatric care and prescription of psychotropic medications it can be 
theorized that, if there is a strong effect of physicians’ peers in the prescribing of psychotropic 
medications, targeting and changing the prescribing behaviors of guideline non-concordant 
(polypharmacy) physicians could lead to a cascading effect in guideline diffusion among other 
physicians within the social structure, resulting in increased concordance with guidelines. Thus, 
it is very important to examine if there is peer-influence on the prescribing practices of 
physicians prescribing psychotropic medications to children and adolescents with mental 
disorders. In order to examine the physician peer-influence in the current study we developed 
physician patient-sharing networks using the administrative claims data from Texas Children’s 
Health Plan and applied the concepts and techniques of Social Network Analysis (SNA).  
Social Network Analysis is a set of theories and techniques used to understand how social 
relationships (e.g., friendship, advice seeking, and discussion) influence behaviors.25-28 SNA is 
commonly used to study relationships between individuals and communities as they interact with 
each other. In the healthcare domain, social network analysis has been used to analyze health 
care networks, addressing topics such as the exchange of clinical advice, the diffusion of new 
pharmaceuticals, or organizational performance and cost-efficiency.23, 24, 29, 30 The studies on 
diffusion of new pharmaceuticals have used SNA to analyze the influence of opinion leaders or 
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key action leaders on daily prescribing practices.24 SNA can help examine physicians’ behaviors 
in the context of their professional social structure (network) where they communicate, 
collaborate, compete and exert influences on each other. SNA provides a unique perspective to 
understand the underlying reasons of prescribing decisions and medication errors. 
The objective of this study was to examine the effect of physician peer-influence on the 
prescribing of psychotropic polypharmacy among children and adolescents treated for 
mental/behavioral disorders. The measures of social network analysis that were used to examine 
the peer-influence were affiliation-based peer influence (exposure through sharing same patients) 
and network influence based on structural equivalence (exposure through occupying similar 
network position). A multilevel statistical analysis was conducted to model the association 
between these network influence measures and prescription behavior, controlling for the clinic 
level, physician level and patient level factors that might be associated with psychotropic 
polypharmacy.  
METHODS  
Study Design and Data Source:  
A retrospective cross-sectional study was conducted using the administrative claims data 
from Texas Children’s Health Plan (TCHP) for the period of July 1, 2013 to June 30, 2015. Data 
was obtained for children and adolescents who were ever diagnosed with mental/behavioral 
disorders identified using ICD 9-CM codes (Appendix A) and who had continuous enrollment 
throughout the study period. TCHP is the nation’s first health maintenance organization (HMO) 
created just for children. It is an administrator for the State Children’s Health Insurance Program 
(CHIP) and STAR/Medicaid managed care programs through a contract with the state Medicaid 
administrator. TCHP has more than 400,000 members and over 1,100 primary care physicians, 
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3,200 specialists and 60 hospitals that provide service and patient care to these members. Of the 
400,000 members 68% are Hispanics, 16% are Caucasians, 9% are African Americans and the 
rest are other racial/ethnic groups. TCHP data contains information on outpatient medical claims, 
and pharmacy claims. It also provides information on the physician that was involved in the 
care/treatment during each patient visit (claim) such as the physician ID, gender, and specialty. 
Additionally, the data includes information on patient characteristics e.g. patient age, gender, and 
race. The data is de-identified in accordance with the Health Insurance Portability and 
Accountability Act (HIPAA) standards.  
Study Sample:  
The study included individuals who: a) were 0 to 18 years of age (children and 
adolescents), b) were diagnosed with a mental/behavioral disorder, c) had at least one pharmacy 
claim of psychotropic medication, and d) received prescription for psychotropic medication from 
single prescriber throughout the study period. Further, these individuals were required to be 
continuously enrolled in the Texas Children Health Plan. Individuals who received prescription 
of psychotropic medication from multiple prescribers during the study period were excluded 
from the study. The psychotropic medications considered in the study included: medications for 
attention-deficit hyperactivity disorder such as stimulants, non-stimulant (atomoxetine), alpha-
agonists (guanfacine, clonidine); anti-depressant medications (selective serotonin norepinephrine 
reuptake inhibitors, serotonin reuptake inhibitors, and tricyclic antidepressants); antipsychotic 
agents (first and second generation); lithium; anticonvulsant mood-stabilizers (such as 
divalproex, oxcarbazepine, carbamazepine, lamotrigine), and anxiolytics (such as hydroxyzine 
and benzodiazepines).  
Two-mode network data and Peer-influence Measures: 31, 32 
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This study measured physician peer-influence based on co-membership in events (sharing 
of patients). We assumed that sharing of patients increases the probability of forming 
professional relationships among physicians. The two-mode network data was used to 
operationalize the peer-influence measures. In the two-mode network data, structural variables 
are measured on two set of nodes. In case of this study, the first mode is a set of physicians 
within the Texas Children’s Health Plan caring for mental/behavioral health patients and the 
second mode is the set of patients to whom the physicians in the first set prescribed psychotropic 
medications. Such a network is called as the affiliation network with each physician (indexed in 
row), with each patient (indexed in column) in the N×K matrix A, with each entry in the matrix 
A equal to 1 if the physician (row actor) prescribed psychotropic medication to the patient 
(column event), and 0 otherwise. Two measures of peer-influence were used in this study 1) 
affiliation exposure (representing cohesion) and 2) structural equivalence exposure (representing 
similarity). Cohesion represents the direct connection between the peers in a network. It indicates 
that the individual has ties with other individuals within the network who can influence that 
individual through frequent and direct communication.32, 33 On the other hand, structural 
equivalence represents “the degree of similarity of actor network profiles in which two 
individuals are considered proximate to the extent that they have the same pattern of 
interpersonal relations with others”. 32, 34 Historically network measures of cohesion and 
structural equivalence have been used to study the diffusion of pharmaceutical prescription 
behaviors of physicians. The effect of cohesion on the diffusion of tetracycline prescription 
behaviors of physicians has been studied previously by Coleman and colleagues35 which was 
later reanalyzed by Burt34 to study the effect of structural equivalence on diffusion of tetracycline 
and to differentiate it from cohesion based influence.          
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Affiliation Exposure (AE):  
We used the affiliation exposure model (Fujimoto et al., 2011; Fujimoto et al., 2012) to 
measure the extent to which a physician is exposed to the polypharmacy prescribing behavior of 
other physicians via sharing of patients. It was computed using the affiliation matrix A, in which 
the rows indexed individual physicians, and the columns indexed all the patients with 
mental/behavioral disorders. This affiliation matrix was then multiplied by its transpose to create 
a one-mode physician-by-physician co-participation matrix, C, where each off-diagonal entry 
represents the number of patients shared between the physician pair, and on-diagonal entry 
represents the number of patients each physician had. The co-participation matrix, C, was then 
row-normalized by dividing each entry by the row total of the C matrix to ensure that the entry 
values range from 0 to 1, but the diagonal entries were suppressed by setting them to zero (but in 
a regression analysis, it was used as one of the controlled variables). Finally, the normalized co-
participation matrix, C, was multiplied by the vector representing the polypharmacy prescribing 
behavior of each alter. The resulting vector is the affiliation exposure vector that represents the 
level of being exposure to the polypharmacy prescribing behavior of other physicians with whom 
they shared patients (ranging from 0 to 1). 
Structural Equivalence Exposure (SE): 
The calculation of Structural Equivalence Exposure was computed using a one-mode 
physician-by-physician co-participation matrix, C, to compute the structural equivalence matrix 
S (diagonal values were ignored) developed by calculating the Pearson correlation for all non-
adjacent actors. This structural equivalence matrix S was then row-normalized by dividing each 
entry by the row total of the S matrix. Finally, the normalized structural equivalence matrix, S, 
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was multiplied by the vector representing the polypharmacy prescribing behavior of each alter. 
The resulting vector was the structural equivalence exposure vector (H).  
The structural equivalence exposure measures the degree to which an actor (physician) is 
exposed to the behavior (polypharmacy prescribing behaviors) of their structurally equivalent 
peers. Social influence based on structural equivalence puts emphasis on the 
competition/comparison between ego and alter31, 34. We assumed that the more similar two 
people are in the network, the more substitutable they are and may lead to increased feelings of 
competition. People who occupy similar structural positions (in terms of patterns of relations 
with all other actors in the network) will influence each other. 
Physician Specialty:  
Physicians were classified as a) Primary Care Physicians (PCPs) (e.g. general medicine, 
family medicine, and internal medicine), b) Specialists (e.g. psychiatry, addiction medicine, and 
psychosomatic medicine), c) Others (all other than PCP and specialist) based on the physician 
specialty reported in the data. For those physicians with missing values for specialty, the 
information was obtained from the National Plan and Provider Enumeration System (NPPES), 
National Provider Identifier (NPI) database using the NPI number for the physicians reported in 
the TCHP data. 
Practice Setting: 
The NPPES NPI database was used to obtain the location of practice for each of the 
physicians in this study, as the TCHP data had information missing for many of the physicians. 
Practice locations’ addresses were converted into geocodes (longitude and latitude coordinates). 
If the geocodes for physicians matched exactly, then the physicians were considered as 
belonging to the same practice, this algorithm has been previously validated by Miller et al36 
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(2014). Depending on the specialty of the physicians practicing in these practice settings (clinics) 
the practice settings were classified as a) PCP only, b) Specialist only, c) Others (non-PCP, non-
specialist) and d) Mix (PCPs, specialists and others all in one practice location). 
Outcome Measure: 
The outcome of interest was whether an individual had at least one episode of multiclass 
psychotropic polypharmacy during the study period, measured as a binary variable (1: Yes, 0: 
No). An episode of multiclass psychotropic polypharmacy was defined as the receipt of ≥ 2 
psychotropic medications from different drug classes concurrently for 60 days or more, with no 
gaps in polypharmacy treatment. The 60-day overlap criterion is the most commonly 
implemented cutoff used to define polypharmacy, it avoids misclassifying instances of cross-
titration as polypharmacy.37, 38 Patients who received psychotropic medications but did not have 
a polypharmacy episode at any time during the study period were classified as non-
polypharmacy cases. Episodes of treatment were identified using the prescription fill date and the 
days’ supply information available from the pharmacy claims. Before measuring the episodes, 
overlapping days’ supply for the same medication were carried forward assuming that the patient 
finished the current prescription before starting on the refill prescription. Gaps in fills of the 
same medication of ≤ 15 days were allowed and adjusted in the calculation of the overlap. 
Further, the overlap was defined by drug class and not specific medications within class, so it 
was not necessary for a single medication within a class to overlap by ≥ 60 days with a particular 
medication in another class. Only unique combinations of drug classes of at least 60 days were 
considered.  
Statistical Analysis:  
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Descriptive statistics, including frequencies and mean (± SD) were used to characterize 
patients’ demographic and clinical characteristics, physician characteristics and practice (clinic) 
characteristics. The differences between patient groups (polypharmacy/non-polypharmacy) were 
analyzed using t-tests and Chi-square tests. A-priori significance level of p<0.05 was chosen for 
all comparisons.  
Multilevel generalized linear mixed models (GLIMMIX) with log link function was 
applied to test the association between prescriber-level peer-influence measures (affiliation 
exposure, structural equivalence) and patient-level risks of receiving multi-class psychotropic 
polypharmacy (dependent variable). The data was structured as patients nested under prescribers 
nested within each practice. A three-level hierarchical analysis that accounts for the nesting 
effect allowed to test for significant prescriber-level effects while controlling for patient-level 
covariates and practice-level clustering. In addition to the main independent variables (network 
measures for peer influence), the 3-level GLIMMIXs also adjusted for practice level covariates 
(practice size, type of practice), prescriber level covariates (gender and specialty), and patient 
level covariates (patient age, gender, race; number of mental/behavioral disorders diagnosed; 
type of mental/behavioral disorder diagnosed; and whether a specialist was involved in 
treatment). Two separate GLIMMIX models were conducted, one for affiliation exposure and the 
other for structural equivalence exposure. Network measures were calculated using UCINET 6 
software (Analytic Technologies, Harvard, MA) and Microsoft Excel software. All statistical 
analyses were conducted by using SAS 9.3 software (SAS Institute, Inc, Cary, NC).  
The study was reviewed and approved by the University of Houston Institutional Review Board. 
RESULTS 
Patient level descriptive statistics: 
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A total of 24,147 children and adolescents were diagnosed with a mental/behavioral 
disorder and had at least one pharmacy claim of psychotropic medication during the study 
period. Of these 13,045 (54.02%), individuals were prescribed psychotropic medications by 
single prescriber throughout the study period. The demographic and clinical characteristics of the 
children and adolescents on psychotropic medications, along with the unadjusted results of 
differences between the non-polypharmacy and the polypharmacy groups are provided in Table 
M3.1. Majority of the patients in both non-polypharmacy and polypharmacy group were male, 
62.38% and 66.73% respectively. Non-polypharmacy patients were predominantly Hispanic 
(46.35%), while patients experiencing psychotropic polypharmacy were predominantly 
Caucasian (38.10%). The mean age of patients was higher in the polypharmacy group as 
compared to the non-polypharmacy group (10.15 ± 3.46 vs. 9.66 ± 4.07, p<0.001). Higher 
proportion of patients experiencing psychotropic polypharmacy were diagnosed with multiple 
mental/behavioral disorders compared to non-polypharmacy cases (60.34% vs. 38%, p<0.001). 
The most common diagnosis among both polypharmacy and non-polypharmacy groups was 
attention-deficit hyperactivity disorder, with polypharmacy group having a substantially higher 
proportion (84.42% vs. 66.42%, p<0.001). Diagnosis of bipolar disorder(s) was almost four 
times higher among the patients experiencing psychotropic polypharmacy as compared to non-
polypharmacy patients (30.34% vs. 8.24%, p<0.001). A higher proportion of patients who 
experienced psychotropic polypharmacy were diagnosed with depression (16.67% vs. 11.36%, 
p<0.001) and schizophrenia (4.29% vs. 2.57%, p<0.001) as compared to the non-polypharmacy 
patients. On the other hand, a lower proportion of patients experiencing psychotropic 
polypharmacy were diagnosed with learning disorder(s) compared to the non-polypharmacy 
group (8.71% vs. 14.76%, p<0.001). A substantially higher proportion of patients experiencing 
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psychotropic polypharmacy had a specialist involved in the treatment (79.73% vs. 35.78%, 
p<0.001) as compared to those patients who were identified as non-polypharmacy. 
About 74% of the patients experiencing polypharmacy were prescribed medications by a 
male physician as compared to about 54% of non-polypharmacy patients (p<0.001). A 
comparatively higher proportion of patients experiencing polypharmacy were provided treatment 
by a specialist throughout the study period as compared to the non-polypharmacy patients 
(76.04% vs. 35.64%). 
Physician and Practice level descriptive statistics: 
Table M3.2 presents the physician and practice setting characteristics. Most of the 
physicians in the patient-sharing network were females (52.95%) and primary care physicians 
(61.42%). Among all type of practice settings, the practices with PCPs only were the most 
common (57.79%), followed by others (19.30%), Specialist only (13.88%) and Mix (9.03%). 
The average number of physicians per setting was 1.86 (±3.52). 
Physician peer-influence measures:  
 The average affiliation exposure for the physicians in this patient-sharing network was 
0.29 ± 0.31 (median= 0.21, range= 0-1) and the average structural equivalence exposure in this 
patient sharing network was 0.15 ± 0.53 (median= 0.22, range= -15.93-2.05). 
Multilevel Logistic Regression model: 
Table M3.3 and Table M3.4 summarize the results of the multilevel logistic regression 
model for affiliation exposure and structural equivalence exposure respectively. 
Practice level factors: 
The multilevel models showed that there was significant variation in the likelihood of 
receiving psychotropic polypharmacy across different practice settings. Statistics showed that 
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about 34% of the variation in the receipt of psychotropic polypharmacy was explained by the 
practice settings, leaving the rest to be explained by physicians, patient related factors or other 
factors. However, practice size and type of practice were not significantly associated with the 
receipt of psychotropic polypharmacy in both the models. 
Physician level factors:  
Each unit increase in affiliation exposure from the mean was associated with 77% higher 
likelihood of receiving psychotropic polypharmacy (OR=1.766; 95% CI 1.027-3.037) which 
implies that having more patient sharing relationship with a polypharmacy prescriber was 
associated with a physician’s prescribing behavior (Table M3.3). In case of structural 
equivalence exposure, each unit increase from the mean was associated with almost 4-times 
higher likelihood of receiving psychotropic polypharmacy (OR=4.236; 95% CI 2.071-8.666). 
This indicates that, more similar the position of a pair of physicians in a physician patient-
sharing network, expressed as their relationship with all other physicians within the network, the 
more likely they will have similar behavior in terms of prescribing psychotropic polypharmacy 
(Table M3.4). 
Other than the physician-level peer-influence measures, physician specialty was 
significantly associated with the receipt of psychotropic polypharmacy among patients with 
mental/behavioral disorders. Patients treated by specialists throughout the study period had about 
3 times higher likelihood of receiving psychotropic polypharmacy as compared to patients 
treated by primary care physicians (AE model: OR=3.627; 95% CI 2.174-6.053 and SE model: 
OR=3.532; 95% CI 2.113-5.904). Physician gender was not significantly associated with the 
receipt of polypharmacy among patients.  
Patient level factors: 
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The odds ratios and confidence intervals for the patient level factors for AE model and 
SE model are presented in Table M3.3 and Table M3.4 respectively. Males had a 14% higher 
likelihood of experiencing psychotropic polypharmacy compared to females. As compared to 
African Americans, Caucasians were 63% more likely to experience polypharmacy while 
Hispanics were 25% less likely to experience polypharmacy. Patients diagnosed with ADHD, 
bipolar disorder(s) and depression had 2.5 times, 2.7 times and 1.3 times higher likelihood of 
experiencing polypharmacy respectively, while patients diagnosed with adjustment disorder(s) 
were 25% less likely to experience psychotropic polypharmacy. 
DISCUSSION 
 This is the first study to examine the effects of affiliation exposure (through sharing 
common patients) and structural equivalence exposure (occupying similar position in patients-
sharing network), as measures of peer-influence, on the prescribing behaviors of physicians, 
resulting in the receipt of psychotropic polypharmacy in children and adolescents with 
mental/behavioral disorders. A positive relationship was observed between affiliation exposure 
and the probability of receiving psychotropic polypharmacy. Results showed that physicians who 
are exposed to the polypharmacy prescribing behavior of other physicians via direct patient-
sharing ties are more likely to prescribe psychotropic polypharmacy. The higher the extent of 
exposure to polypharmacy prescribing behavior of direct ties, higher is the likelihood of 
prescribing polypharmacy. Previous studies have shown that physicians who share greater 
number of patients communicate with each other and tend to have stronger collaborative 
relationships. A study by Barnett et al validated that physicians who shared 8 or more patients 
had 80% probability of having an information-sharing relationship.30 Physician peers having 
direct ties communicate with each other regarding the diagnostic and treatment practices that 
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they implement in their patient panel. Thus, polypharmacy prescribing behavior of one physician 
can be adopted by the other physician peers in such direct patient-sharing ties.    
It was found that structural equivalence exposure had a stronger association with 
psychotropic polypharmacy than the affiliation exposure. The reason for this may be that, 
affiliation resulting from sharing of patients might not necessarily represent direct 
communication between the physicians. Many times physicians’ share patients with each other 
but do not come in direct contact. For example, with the advent of electronic medical records, the 
patient’s diagnosis, treatment and care history directly reaches other physician with whom the 
patient is shared, but there is no direct communication between the two physicians.  
Structural equivalence exposure was the single most prominent factor associated with the 
receipt of psychotropic polypharmacy even after controlling for practice-level, physician-level 
and patient-level covariates. Structural equivalence is driven by social comparison such as 
imitation or competition between the ego and alter.39 Usually, exact match of structural 
equivalence is rare in a large network of physicians thus the degree of structural equivalence is 
measured to approximate equivalence. According to Burt (1982) 40 “structural equivalence 
predicts that two people identically positioned in the flow of influential communication will use 
each other as a frame of reference for subjective judgments and so make similar judgments even 
if they have no direct communication with each other”. Structurally equivalent actors have same 
structural characteristics and are identically positioned in the network, making them 
substitutable. As a result, structurally equivalent actors use one another to evaluate each other’s 
beliefs, attitudes and behaviors.32 In context of the current study, structurally equivalent 
physicians occupy the same position in the social structure and proximate a pattern of relations 
with other physicians in the network. According to the social network theory, the more similar 
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two physicians’ relations with other physicians are, that is, the more one physician could 
substitute for another physician in his/her role or relations, the more intense the physician’s 
feeling of competition with the other. These competing physicians tend to use one another to 
evaluate their relative adequacy. It is likely that if one of the physician in the structurally 
equivalent pair prescribes psychotropic polypharmacy to treat his/her patients in order to achieve 
desired outcomes, the other physician will imitate the behavior either through sense of 
competition or comparison to achieve similar outcome in his/her patient panel. Additionally, in 
case of lower density networks structural equivalence may be the only source of diffusion as the 
ties between the directly connected actors are not dense (strong) enough for direct influence 
through affiliation.39 
 In addition to the network measures of peer-influence, there were practice-level, 
physician-level and patient-level factors that were strongly associated with the receipt of 
psychotropic polypharmacy among children and adolescents with mental/behavioral disorders. 
The likelihood of receiving psychotropic polypharmacy differed across practice settings, 
however the size and type of practice was not significantly associated with psychotropic 
polypharmacy. It is possible that the variation in the likelihood of receiving polypharmacy could 
have been observed due to differing organizational structures, processes of care and policies 
implemented in these practices. Findings suggest physician related differences in the likelihood 
of receiving psychotropic polypharmacy, especially the likelihood of experiencing psychotropic 
polypharmacy varied based on the specialty of the physician involved in the treatment. Children 
and adolescents who were prescribed psychotropic medications by specialists (psychiatrists) 
throughout the study period had a significantly higher probability of experiencing psychotropic 
polypharmacy as compared to those who were treated by primary care physicians.  This finding 
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is consistent with the previous literature. The probable reason for this might be that specialists 
have advanced training in the care and treatment of psychiatric disorder, thus are more 
comfortable prescribing psychotropic medications than the primary care physicians.41 Other 
reason according to literature is that psychiatrists heavily emphasize on symptom reduction 
rather than the disorder itself leading to prescription of more medications.42-44  
 Patient demographics and clinical characteristics were among the most dominant risk-
factors associated with the receipt of psychotropic polypharmacy. Male patients had a higher 
likelihood of receiving psychotropic polypharmacy. Caucasians had a higher likelihood of 
receiving psychotropic polypharmacy while Hispanics were less likely to experience 
polypharmacy, which might be due to the differences in the care seeking behaviors of these 
racial groups. Caucasians tend to discuss their symptoms and seek treatment options while 
Hispanics are less accepting of treatment for mental/behavioral disorders.45 As expected and 
consistent with the literature, co-occurring mental/behavioral disorders were among the strongest 
predictors of polypharmacy, specifically ADHD, bipolar disorder(s) and depression. In some 
instances these disorders may lead to clinical complexity in patients justifying the need for use of 
psychotropic polypharmacy. However, appropriate follow-up and monitoring of these patients is 
all the more important to make sure that psychotropic polypharmacy is effective in reducing 
symptoms and not leading to unwanted side effects. 
There were several limitations to this study. First, this was a cross-sectional study thus 
only association between the peer-influence measures and psychotropic polypharmacy could be 
observed. Longitudinal relationships and change in exposure over time could not be accounted 
for. Second, the structural dimensions of the overall network structure such as network density, 
or that of individuals such as centrality was not measured. Third, the network measures of peer-
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influence were calculated using the administrative claims data based on the assumption that 
physicians who share patients are connected with each other and have direct ties, however it 
might not be necessarily true as patients might visit two different physicians without direct 
communication between those physicians. Lastly, clinical severity of the patient could not be 
assessed using the claims data. 
CONCLUSIONS 
 This study found that physician peer-influence was strongly associated with the 
prescription of psychotropic polypharmacy. Specifically, peer-influence was observed between 
physicians having direct ties with other physicians through patient-sharing and among those 
physicians who occupied similar structural positions within the physician network. The greater 
the extent of exposure to the polypharmacy prescribing behavior of direct ties, greater was the 
likelihood of polypharmacy. Additionally, more similar the physician’s pattern of relations with 
all other physicians in the network who ever prescribed polypharmacy the higher was the 
likelihood of polypharmacy. Further, differences were observed in the likelihood of receiving 
psychotropic polypharmacy across different practice settings, physician specialties and patient’s 
clinical characteristics. The findings support the hypothesis that targeting and changing the 
prescribing behaviors of guideline non-concordant physicians can lead to diffusion of guideline 
concordant practices among other physicians. 
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Table M3. 1 Demographic and clinical characteristics 
Characteristic 
Single prescriber involved in treatment (N=13,045; 100%) 
Non-polypharmacy  
 (N=11,575; 88.73%)  
Psychotropic polypharmacy  
(N=1,470; 11.27%) 
Patient Gender 
Male 7220 (62.38) 981 (66.73) 
Race* 
African American 2733 (23.61) 411 (27.96) 
Alaskan 27 (0.23) 5 (0.34) 
Asian 175 (1.51) 7 (0.48) 
Caucasian 2908 (25.13) 560 (38.10) 
Hispanic 5364 (46.35) 452 (30.75) 
Not reported 367 (3.17) 35 (2.38) 
Age group* 
0-3 691 (5.97) 8 (0.54) 
4-8 4197 (36.26) 548 (37.28) 
9-12 3455 (29.85) 500 (34.01) 
13-18 3232 (27.92) 414 (28.16) 
Mean (± SD)* 9.66 (4.07) 10.15 (3.46) 
Number of mental/behavioral disorders diagnosed* 
0 562 (4.86) 12 (0.82) 
1 6615 (57.15) 571 (38.84) 
2-4 4214 (36.41) 814 (55.37) 
≥5 184 (1.59) 73 (4.97) 
Mean (± SD)* 1.56 (0.99) 2.10 (1.23) 
Type of  mental/behavioral disorder diagnosed 
ADHD* 7688 (66.42) 1241 (84.42) 
Bipolar Disorder(s)* 954 (8.24) 446 (30.34) 
Depression* 1315 (11.36) 245 (16.67) 
Anxiety* 1308 (11.30) 217 (14.76) 
Learning Disorder(s)* 1708 (14.76) 128 (8.71) 
Adjustment Disorder(s) 1112 (9.61) 134 (9.12) 
Conduct Disorder 1144 (9.88) 202 (13.74) 
Oppositional Defiant Disorder 832 (7.19) 220 (14.97) 
Schizophrenia 297 (2.57) 63 (4.29) 
Hospitalization/ ER-visit* 
Yes 1103 (9.53) 202 (13.74) 
Specialist visited 
Yes* 4142 (35.78) 1172 (79.73) 
Physician Gender 
Male 6181 (54.18) 1208 (74.20) 
Physician Specialty 
Specialist 4066 (35.64) 1238 (76.04) 
Primary Care Physicians 6272 (54.97) 354 (21.74) 
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Others 1071 (9.39) 36 (2.21) 
 Type of Practice  
Specialist only 2961 (25.95) 993 (61.00) 
Primary Care Physicians only 5116 (44.84) 303 (18.61) 
Mix 2924 (25.63)  320 (19.66) 
Others 408 (3.58) 12 (0.74) 
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Table M3. 2 Physician and Practice setting characteristics 
Characteristic N (%) 
Physician Gender 
Male 733 (47.05) 
Female 825 (52.95) 
Physician Specialty 
Specialist 219 (14.06) 
Primary Care Physicians 957 (61.42) 
Others 382 (24.52) 
Practice Type 
Specialist Only 123 (13.88) 
Primary Care Physicians Only 512 (57.79) 
Mix 80 (9.03) 
Others 171 (19.30) 
Practice Size 
Mean (± SD) 1.86 (±3.52) 
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Table M3. 3 Multilevel Logistic Regression model to determine the association between 
affiliation exposure and psychotropic polypharmacy 
Characteristic OR 95% CI p 
PRACTICE CHARACTERISTICS 
Practice Size 0.999 0.969-1.030 0.957 
 
Type of Practice (Ref: Primary Care only) 
Specialists only 1.687 0.859-3.311 0.129 
Mix 1.073 0.599-1.922 0.813 
Others only 0.715 0.249-2.054 0.534 
 
PHYSICIAN CHARACTERISTICS 
Affiliation Exposure 1.766 1.027-3.037 0.040 
 
Physician Specialty (Ref: Primary Care) 
Specialist 3.627 2.174-6.053 <0.001 
Others 1.232 0.635-2.388 0.537 
 
Physician Gender (Ref: Female) 
Male 1.272 1.024-1.581 0.039 
 
PATIENT CHARACTERISTICS 
Patient age 0.997 0.979-1.015 0.718 
 
Number of mental/behavioral disorders diagnosed 1.066 0.885-1.285 0.501 
 
Patient Gender (Ref: Female) 
Male 1.147 1.007-1.307 0.030 
 
Patient Race (Ref: African American) 
Alaskan/American Indian 1.575 0.498-4.981 0.440 
Asian/pacific 0.306 0.134-0.701 0.005 
Caucasian 1.639 1.395-1.926 <0.001 
Hispanic 0.748 0.635-0.881 <0.001 
No ethnicity 1.405 0.942-2.097 0.095 
 
Mental/behavioral Disorders Diagnosed (Ref: No) 
ADHD 2.589 2.010-3.334 <0.001 
Bipolar Disorder(s) 2.746 2.131-3.539 <0.001 
Depression 1.343 1.026-1.758 0.032 
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Anxiety 1.338 1.020-1.755 0.036 
Learning Disorder(s) 0.788 0.587-1.057 0.112 
Adjustment Disorder(s) 0.750 0.564-0.996 0.047 
Conduct Disorder 1.025 0.778-1.352 0.859 
Oppositional Defiant Disorder 1.173 0.893-1.540 0.251 
Schizophrenia 1.035 0.712-1.504 0.859 
 
ER-visit/hospitalization 1.020 0.834-1.248 0.844 
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Table M3. 4 Multilevel Logistic Regression model to determine the association between 
structural equivalence exposure and psychotropic polypharmacy 
Characteristic OR 95% CI p 
PRACTICE CHARACTERISTICS 
Practice Size 0.999 0.968-1.030 0.944 
 
Type of Practice (Ref: Primary Care only) 
Specialists only 1.690 0.854-3.345 0.132 
Mix 1.040 0.578-1.874 0.895 
Others only 0.653 0.223-1.911 0.436 
 
PHYSICIAN CHARACTERISTICS 
Structural Equivalence Exposure 4.236 2.071-8.666 <0.001 
 
Specialty (Ref: Primary Care) 
Specialist 3.532 2.113-5.904 <0.001 
Others 1.329 0.682-2.591 0.403 
 
Physician Gender (Ref: Female) 
Male 1.221 0.981-1.521 0.074 
  
PATIENT CHARACTERISTICS 
Patient age 0.997 0.979-1.016 0.751 
 
Number of mental/behavioral disorders diagnosed 1.066 0.885-1.285 0.500 
 
Patient Gender (Ref: Female) 
Male 1.148 1.007-1.308 0.039 
 
Patient Race (Ref: African American) 
Alaskan/American Indian 1.537 0.483-4.887 0.467 
Asian/pacific 0.305 0.134-0.696 0.005 
Caucasian 1.634 1.391-1.920 <0.001 
Hispanic 0.745 0.632-0.878 <0.001 
No ethnicity 1.392 0.931-2.082 0.107 
 
Mental/behavioral Disorders Diagnosed (Ref: No) 
ADHD 2.556 1.984-3.292 <0.001 
Bipolar Disorder(s) 2.743 2.128-3.536 <0.001 
Depression 1.346 1.028-1.763 0.031 
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Anxiety 1.338 1.019-1.755 0.036 
Learning Disorder(s) 0.786 0.585-1.055 0.109 
Adjustment Disorder(s) 0.748 0.563-0.994 0.045 
Conduct Disorder 1.028 0.779-1.355 0.847 
Oppositional Defiant Disorder 1.171 0.892-1.538 0.255 
Schizophrenia 1.045 0.719-1.519 0.816 
 
ER-visit/hospitalization 1.019 0.833-1.246 0.857 
 
 
